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Purified retroviral Gag proteins can assemble in vitro to form immature virus-like 
particles (VLPs). By electron cryo-tomography, Rous sarcoma virus (RSV) VLPs show 
an organized hexameric lattice consisting chiefly of the capsid (CA) domain, with 
periodic stalk-like densities below the lattice. I hypothesize that the structure underlying 
these densities is formed by amino acid residues immediately downstream of the folded 
CA, namely the short spacer peptide SP, along with a dozen flanking residues. These 
24 residues comprise the SP assembly (SPA) domain, and I propose that neighboring 
SPA units in a Gag hexamer coalesce to form a six-helix bundle. Using in vitro 
assembly, alanine scanning mutagenesis, and biophysical analyses, I have further 
characterized the structure and function of SPA. Most of the amino acid residues in SPA 
could not be mutated individually without abrogating assembly, with the exception of a 
few residues at the N- and C-termini as well as three hydrophilic residues within SPA. I 
interpret these results to mean that the amino acids that do not tolerate mutations 
contribute to higher-order structures in VLPs. Hydrogen-deuterium exchange analyses 
of unassembled Gag in comparison with assembled VLPs showed strong protection at 
the SPA region, consistent with a higher-order structure. Circular dichroism revealed 
that a 29mer SPA peptide shifts from a random coil to a helix in a concentration-
dependent manner. Analytical ultracentrifugation showed concentration-dependent self-
association of the peptide into a hexamer. Taken together, these results provide the first 
convincing evidence for the formation of a critical six-helix bundle (6HB) in RSV Gag 
assembly. I have modeled the RSV 6HB using structural and sequence homology with 
an existing synthetic 6HB and discovered a salt-bridge that may help stabilize the 
helical bundle. 
In an attempt to assess the structure of the immature retroviral core, which is 
made solely of Gag, I also crystallized several proteins containing the minimum regions 
of Gag required for immature assembly. Due to the inherent flexibility of Gag, which is a 
multi-domain protein, no crystal structure has been reported thus far of a Gag-like 
protein. I have shown that it is possible to crystallize a “minimal Gag”, but that the 
crystals are difficult to optimize to the quality required for X-ray diffraction. I have also 
crystallized the aforementioned SPA peptide in order to determine the atomic-level 
structure of the putative 6HB. Unfortunately, my diffraction results show that the crystal 
packing is disordered. Although much more optimization will likely be required to 
produce crystals that can diffract to high resolution, my work has shown that it is 
possible to crystallize both a Gag-like protein and a peptide corresponding to the SP 
domain. 
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CHAPTER ONE 
INTRODUCTION 
GENERAL INTRODUCTION 
 Retroviruses are a family of enveloped, single-stranded (ss) RNA viruses that 
infect host species from fish to humans and are current and relevant human pathogens. 
The most infamous member of this family is human immunodeficiency virus type 1 (HIV-
1), the causative agent of acquired immunodeficiency syndrome (AIDS), which has 
killed an estimated 25 million people since its initial characterization in the early 1980s, 
including 1.7 million individuals who died of AIDS-related causes in 2011. Another 
retroviral human pathogen is human T-cell leukemia virus type I (HTLV-I). Although 
infection with HTLV-1 does not carry the same rate of mortality as HIV-1, it has been 
associated with diseases such as myelopathy and parasitic superinfection, conditions 
that severely compromise the host’s quality of life, in addition to adult T-cell leukemia.  
As their name suggests, retroviruses possess an enzyme known as reverse 
transcriptase (RT), which converts their genomic ssRNA into double-stranded (ds) DNA 
through a complex series of biochemical reactions. Though RT is the retroviral 
namesake, integrase (IN) is the viral signature. Following reverse transcription, IN is 
transported into the nucleus along with the newly synthesized dsDNA and incorporates 
the viral dsDNA into a host chromosome, literally leaving a genetic imprint in the host. 
Infected cells actively and persistently produce retroviral proteins along with their own 
genetic products, resulting in newly produced virions that continuously re-infect the host.  
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Despite the discovery of the first retroviruses over a century ago by Ellerman and 
Bang, and Rous (Nobel Prize 1966), a cure for retroviral infections has remained 
elusive. The prognosis for infected individuals, however, is far from grim. Around the 
same time as the discovery of RT in 1970 by Temin, Baltimore, and Dulbecco (shared 
Nobel Prize 1975) came a shift of interest in biology from the organism as a whole to 
mechanisms at the molecular level. Since then, scientists have dissected various model 
retroviruses down to the molecular and atomic level and have acquired a great deal of 
knowledge on the retroviral genome, genetic products, life cycle, and interactions with 
their hosts. As a result of this in depth understanding of the mechanisms underlying 
retroviral infection, many antiretroviral treatments exist today to keep HIV-1 infection 
under control and prevent it from progressing to AIDS. Furthermore, new therapies are 
currently being developed to address unexploited targets in the retroviral life cycle. 
CLASSIFICATION OF RETROVIRUSES 
The retroviral family 
The family Retroviridae is divided into two subfamilies: Orthoretrovirinae and 
Spumavirinae. The orthoretroviral family is composed of six genera of pathogenic 
retroviruses. Alpharetrovirus is a genus of avian retroviruses that includes the earliest 
discovered retroviruses: avian leukosis virus (ALV) and Rous sarcoma virus (RSV). The 
genus Betaretrovirus infects mammals and is represented by the Mason-Pfizer monkey 
virus (MPMV), mouse mammary tumor virus (MMTV) and Jaagsikte sheep retrovirus 
(JSRV). Members of the Gammaretrovirus genus also infect mammals, and the 
prototypic species is murine leukemia virus (MLV). Deltaretrovirus is a genus that 
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includes the human pathogen HTLV-I and its close relative HTLV-II, as well as bovine 
leukemia virus (BLV). Epsilonretrovirus is a genus containing two species of fish 
retroviruses: the walleye dermal sarcoma virus (WDSV) and walleye epidermal 
hyperplasia virus (WEHV). Finally, Lentivirus, so named because of its slow disease 
progression, includes viruses that cause immunodeficiency in cats (feline 
immunodeficiency virus, FIV), cows (bovine immunodeficiency virus, BIV), and primates 
(simian immunodeficiency virus, SIV and HIV types 1 and 2). Viruses belonging to the 
subfamily spumaviridae are sometimes called foamy viruses due to the large vacuoles 
that form in infected cells. Spumaviruses have not been conclusively linked to disease 
in hosts from which they have been isolated. Many differences exist between 
spumaviruses and orthoretroviruses at the level of the viral life cycle and at the 
molecular level. Therefore, the topics covered in the remainder of this thesis will apply 
exclusively to orthoretroviruses, unless otherwise noted. An excellent overview of the 
molecular biology of spumaviruses can be found in the review by Maxine Linial [1]. 
Retroviruses are also related to some genetic elements capable of reverse 
transcription. These are known as retroelements and include endogenous retroviruses 
(ERV) and long-terminal repeat (LTR) retrotransposons. Most ERVs are proviruses that 
often have debilitating mutations in one or more viral proteins and can no longer 
produce infectious virions or leave the cell, or they are integrated in non-expressed 
chromosomal regions. However, some ERVs can still become expressed and cause 
infection in their hosts, usually in the presence of certain host factors or “activating” 
agents such as radiation and carcinogens, leading to diseases such as spontaneous 
lymphomas in AKR mice (endogenous MLV) or leukosis in chickens (endogenous avian 
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leukosis virus, EALV and endogenous avian virus, EAV) [2]. LTR retrotransposons are 
similar to ERVs in that they encode their own RT and IN and multiply within the host 
genome by creating new copies of themselves. Although they do not produce infectious 
virus, retroelements may continue to alter their hosts through changes in gene 
expression and chromosomal rearrangement mediated by the LTR, a hallmark DNA 
footprint of reverse transcription and integration generated as a result of the series of 
biochemical acrobatics undertaken by RT. The LTR is a repeated sequence that flanks 
the retroviral genome at both ends and varies in length from approximately 300 bp 
(alpharetroviruses) to over 1200 bp (spumaviruses). The LTR may act as an alternative 
enhancer/promoter site for nearby genes and can also mediate recombination, deletion 
and duplications in the genome simply because of their high copy number. As they are 
found across the eukaryotic domain, retroelements are believed to be the result of 
retroviral integration into the host germ line over the course of evolution. 
ORTHORETROVIRAL LIFE CYCLE 
Early stage 
The retroviral life cycle is roughly divided into two halves, termed “early” and 
“late”. The early stage includes viral binding, entry, uncoating, reverse transcription, 
trafficking, nuclear entry, and integration (Figure 1.1). The virus life cycle begins when 
an infectious virion binds the host cell surface via relatively non-specific interactions. 
Once attached to the cell plasma membrane (PM), viral envelope glycoproteins bind 
specifically to their cognate receptors and mediate fusion between viral and cellular 
membranes. Viral contents, including the capsid that contains two copies of the 
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Figure 1.1: The retroviral life cycle. The early stage of the retroviral life cycle is 
illustrated in steps 1 – 3, while the late stage is in steps 4 – 7.  
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retrovirus ssRNA genome spill out into the cytoplasm, where capsid uncoating and 
reverse transcription take place. Reverse transcription leads to the formation of the pre-
integration complex (PIC): a poorly characterized, integration-competent association of 
viral enzymes, reverse-transcribed DNA, and other proteins, including proteins from the 
host (e.g. LEDG F for HIV-1) that may assist in the retroviral life cycle [3, 4]. The PIC is 
trafficked through the cytoplasm, likely by association with cytoskeletal motor proteins 
and reaches the nucleus. Depending on the species of retrovirus, nuclear entry takes 
place in different ways. Some PICs are actively transported through the nuclear pore, 
possibly through interactions with importins that mediate nuclear entry (RSV, HIV-1), 
while others must wait for the breakdown of the nuclear membrane during cell division 
(MLV). Once inside the nucleus, the dsDNA is inserted into the host genome by 
integrase, which has a preference for highly transcribed regions. The integrated virus, or 
the provirus, is the template from which retroviral RNA can be transcribed [5, 6].  
Late stage 
The late stage of the retroviral life cycle includes the steps following integration: 
transcription, nuclear export, translation, assembly, budding, and maturation (Figure 
1.1). Viral DNA is transcribed as a single long RNA transcript that is alternatively 
spliced. All retroviruses contain three canonical genes: gag, pol, and env, each coding 
for a functionally distinct group of proteins required for the retroviral life cycle. The 
structural proteins, matrix (MA), capsid (CA), and nucleocapsid (NC) are part of the Gag 
polyprotein. The pol reading frame codes for the essential viral enzymes, including IN, 
RT, and protease (PR), and env codes for the envelope glycoproteins, generally known 
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as the surface protein (SU) and the trans-membrane protein (TM). Gag is translated as 
a single polyprotein and the Gag-Pol polyprotein is initiated from the same start codon 
as Gag, but a ribosomal frame-shift or termination suppression at the gag-pol junction 
occurring approximately 5 – 10% of the time results in the production of the longer Gag-
Pol. Both polyproteins are translated from the genome-sized transcript. In the cytosol, 
Gag binds to genome-sized viral RNA transcripts and trafficks to the PM where it 
assembles into the viral core and includes one molecule of Gag-Pol for every 10 – 20 
Gag monomers. Env is produced from a spliced transcript as a long precursor protein 
and hijacks the endoplasmic reticulum (ER)/Golgi-mediated trafficking system. Within 
the ER, Env oligomerizes into a trimer and is glycosylated. As it progresses through the 
Golgi, Env is cleaved by a cellular protease into its constituent subunits SU and TM, 
which remain non-covalently associated. SU mediates receptor-binding, while TM 
contains the fusogenic peptide required for the fusion of viral and cellular membranes. 
The mature trimeric envelope glycoprotein is then transported to the cell surface, where 
it joins the assembling Gag and Gag-Pol to form the immature retrovirus. 
At least two molecules of Gag bind to viral RNA with their NC domains, bringing 
the proteins close together and initiating the first step in assembly. Gag also associates 
with the PM via the MA domain, leading to oligomerization and assembly of the viral 
protein core at the PM. The formation of the immature core generates membrane 
curvature, ultimately resulting in a virus particle that buds from the cellular membrane. 
Betaretroviruses are a curious exception, as they assemble fully within the cytoplasm at 
a perinuclear location and are transported to the PM via recycling endosomes. The 
immature virus buds from the PM by exploiting the cellular machinery known as 
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endosomal sorting complexes required for transport (ESCRT), normally used for the 
formation of multivesicular bodies and membrane abscission during cytokinesis. During 
or rapidly following budding, PR is activated through an unknown mechanism and 
cleaves Gag and Gag-Pol to liberate the viral structural proteins and enzymes. The viral 
core undergoes a morphological change in which the immature spherical core takes on 
the appearance of a mature capsid. At this stage, maturation is complete and the 
retrovirus is ready to infect another cell. 
Accessory genes 
Retroviruses may contain genes other than gag, pol, and env. These “accessory” 
genes have evolved myriad functions to assist the virus at different steps of its life cycle. 
Betaretroviruses, deltaretroviruses, epsilonretroviruses, lentiviruses, and spumaviruses 
have genomes that contain accessory genes. For this reason, these viruses are 
deemed to have “complex” life cycles. Alpharetroviruses and gammaretroviruses do not 
have accessory genes and are classified as “simple” retroviruses. Accessory genes are 
a subject of current and ongoing research and are beyond the scope of this introduction. 
VIRION STRUCTURE 
Immature virion organization  
In recent years, development and refinement of high-resolution structure 
determination techniques have lead to a wealth of new information on the late stages of 
the retroviral life cycle, particularly on the way retroviruses organize their cores. The 
retroviral core exists in two forms, immature and mature, that are structurally and 
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morphologically distinct. Figure 1.2 shows the immature core, which is made of an array 
of hexameric Gag polyproteins forming a spherical shell around the viral genome. Gag 
is the retroviral structural polyprotein (Figure 1.3) and comprises three domains 
common to orthoretroviruses: MA, CA, and NC, each of which will be discussed in 
following sections. In the immature core, Gag is organized radially with MA bound to the 
inner viral membrane and the C-terminus of Gag pointing toward the inside of the virion 
[7]. Although MA may be oligomeric in crystal structures, an organized layer consisting 
of the MA domain has not been observed using cryo-EM [8, 9]. The CA domain forms 
an ordered lattice composed of hexameric rings, and the NC domain complexed with 
RNA can be seen as a diffuse density near the center of the immature core.  
Mature virion organization 
Retroviral maturation is a rapid process and very few immature virions are normally 
observed among wild-type virions collected from cells. Maturation takes place when PR 
cleaves Gag into its constituent domains, leading to disassembly of the spherical core, 
followed by reassembly of each liberated domain into its mature conformation [10, 11]. 
The liberated MA remains bound to the viral membrane. A striking morphological 
transformation takes place in CA, which is the major constituent of the organized lattice 
in both the immature core and the mature capsid. The spherical core formed by the CA 
domain of Gag rearranges itself into distinct capsid geometries including conical (HIV-
1), cylindrical (MPMV), and polyhedral (RSV), as observed by EM. The NC-RNA layer 
condenses into a dense globular mass, possibly to fit the NC-RNA complex into the 
spatially restricted confines of the mature capsid [14] (Figure 1.2). 
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Figure 1.2: The morphology and structural organization of immature and mature 
retroviral virions are distinct. A. The immature virion is composed of a lattice of 
radially arranged Gag molecules bound to the viral genomic RNA (red) and enveloped 
by the viral membrane (orange). In RSV, Gag contains four major domains: MA (pink), 
CA (violet), NC (light pink), and PR (blue). Following PR cleavage, the liberated 
structural proteins reassemble into their mature conformation. B. Authentic immature 
virions have a spherical core made up mainly of the CA domain of Gag. The core 
consists of an electron-dense ring around an electron-lucent center, as seen using thin-
section EM (left). Authentic mature virion capsids are morphologically distinct from 
immature cores. In RSV, the capsids are polyhedral, as seen using cryo-EM (right). EM 
images are adapted from Butan et al. and Campbell et al. [12, 13]. 
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Figure 1.3: Schematic diagrams of retroviral Gag proteins from RSV, HIV-1, 
MPMV, MLV and their constituent domains. Inter-domain cleavage sites are 
indicated by vertical lines. All orthoretroviral Gag proteins have in common the MA, CA, 
and NC domains. CA is a two-domain protein and the location of its inter-domain 
junction is shown as a dashed line. 
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Virus-like particles and self-assembly 
Virus-like particle (VLP) is a general name for viral protein-derived assemblies 
that are composed solely of the structural proteins required to form the viral core. VLPs 
are useful for the study of viral core structure as they resemble authentic virions in 
morphology. In retrovirology, the term VLP generally refers to assemblies of Gag, which 
is the only protein required to make the protein shell of immature retroviruses. VLPs can 
be produced by transfecting Gag into cells, which results in the release of spherical 
immature cores enveloped in membrane into the medium. VLPs also self-assemble in 
vitro using purified Gag protein under the appropriate pH and salt conditions (discussed 
in detail in the section on in vitro assembly), and in the presence of certain negatively-
charged molecules such as oligonucleotides or inositol phosphates [15, 16]. In vitro 
assembled VLPs are organizationally identical to authentic virions, but they lack a viral 
membrane [10]. In this dissertation, I will use the term VLP to describe immature, Gag-
derived assemblies, and “capsid assembly” for CA-based assemblies. 
Inhibition of maturation 
To facilitate studies of the immature core in the laboratory, viral maturation can 
be inhibited in a number of ways. Immature virions can be harvested in cells by 
mutating the catalytic Asp in the active site of PR, resulting in non-infectious, immature 
virions containing a spherical core and a full complement of viral proteins [17, 18]. VLPs 
can also be made in cells by transfecting a cellular expression vector containing Gag in 
the absence of Pol. This approach is not suitable for RSV and other avian retroviruses, 
which encode PR as part of the Gag polyprotein. When using these viruses to generate 
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VLPs, PR must be inactivated by mutation or prevented from being expressed by 
introducing an upstream stop codon. Mutating the cleavage sites in Gag is also a viable 
means of preventing maturation, but despite several analyses, mutations that inhibit PR 
processing remain poorly characterized, except in the case of HIV-1 [14, 19-22]. 
Small molecules that inhibit maturation, either by binding to PR or to the Gag 
lattice, have been developed as antiretroviral compounds. PR inhibitors have been 
hugely successful and are often used as part of antiretroviral treatment programs. Gag-
binding inhibitors are a newer class of antiretrovirals generally referred to as maturation 
inhibitors. The most extensively studied member of this class is bevirimat, a betulinic 
acid-derived compound that has been shown to bind to the assembled immature Gag 
lattice rather than to individual Gag proteins, and that prevents PR-mediated cleavage 
of the CA-SP1 domain junction [23-26]. However, bevirimat was not successful in 
clinical trials as resistance develops rapidly [26-29]. Other HIV-1 Gag-binding 
compounds are still actively under study, including the Pfizer compound PF-46396 that 
binds a putative pocket formed by SP1 and the major homology region (MHR) [30]. 
GAG POLYPROTEIN 
MA domain 
The MA domain associates with the PM via its N-terminal portion, also called the 
membrane-binding domain (MBD). MA employs several distinct mechanisms for 
membrane-binding: 1) a patch of positively charged amino acids in the MBD common to 
all MA crystal structures and structural models [31] and 2) an N-terminal myristoylation 
present in some retroviruses, believed to help anchor MA into the PM. The positively 
 14 
 
charged amino acids, also known as the basic patch, interact extensively with the inner 
leaflet of the PM, which is enriched in negatively charged phospholipids such as 
phosphatidylserine (PS) and phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P2). The N-
terminal myristate has been studied in depth using HIV-1 MA and is generally accepted 
to be a switch for enhanced membrane binding following PI(4,5)P2 binding, which triggers 
myristate exposure and insertion into the membrane bilayer and is essential for HIV-1 
viral release [17, 32-36]. PI(4,5)P2 binding in HIV-1 was structurally characterized by 
Saad et al., who showed that HIV-1 MA has a specific hydrophobic PI(4,5)P2 binding 
pocket that is not shared among non-myristoylated retroviruses such as RSV [32, 37].   
Gag-driven multimerization is also an essential component to MA binding to the 
PM in both RSV and HIV-1, and may contribute to either myristate exposure or 
enhanced electrostatic association [35, 38, 39]. A recent set of experiments by Dick et 
al. examined the different states of oligomerization and their effects on MA-binding to 
the PM. The authors showed that monomeric MA protein is mainly cytoplasmic, while 
artificially generated dimeric and hexameric MA are clearly membrane-bound when 
transfected into cells. These results can be recapitulated in an in vitro system of purified 
protein and liposomes, in which monomeric MA is largely non-liposome-bound, while 
hexameric MA is primarily liposome-bound (Dick et al., in preparation).   
The structure of MA and MA fragments has been solved for several retroviruses, 
including HIV-1 (non-myristoylated and myristoylated), RSV, MPMV, MLV, EIAV, SIV 
and HTLV-II [32, 38, 40-50]. They have in common four core alpha helices, although a 
fifth helix was observed in an unpublished dimeric structure of RSV MA and may be 
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involved in dimerization (Richard Kingston, personal communication). HIV-1 MA has 
also been crystallized in a trimeric form (PDB ID: 1HIW) [40], although it is not clear 
whether these multimerization states reflect biologically relevant interfaces or artifacts of 
crystal packing.  
CA domain 
CA is the main component of the retroviral core and mediates the majority of 
protein-protein interactions in both the immature and mature cores. Based on 
comparative analyses of high-resolution structures of both the immature and mature 
cores, it has been inferred that during maturation, CA disassembles and reassembles 
into the mature viral capsid [10]. The detailed protein-protein interactions that lead to the 
assembly of the retroviral core will be discussed in detail in the following sections.  
CA is a two-domain protein with independently folding N- and C-terminal 
domains, commonly known as CANTD and CACTD, connected by a short flexible linker 
(Figure 1.4). CANTD is a globular domain consisting of seven α-helices of varying length, 
while CACTD is composed of four α-helices. The atomic-level structure of CA has been 
determined using constructs in various states of oligomerization, including CANTD alone, 
CACTD alone, fragments of CA in complex with other molecules such as Fab fragments 
and cyclophilin A, and full-length CA as a monomer, dimer, and hexamer [51-66]. Like 
MA, the structure of CA, though not the amino acid sequence, is highly conserved 
across all retroviral species [56, 62]. In the free CA protein, the first residue is invariably 
a proline that forms a salt bridge with a conserved aspartic acid residue in helix 3 (D52 in 
RSV and D51 in HIV-1) [52, 59]. The formation of this salt bridge is one of the events 
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Figure 1.4: CA is a two domain protein consisting of CANTD and CACTD. CA is 
structurally conserved among orthoretroviruses, although this structure of HIV-1 CA is 
the only crystal structure of full-length CA. The seven N-terminal helices make up CANTD 
(green oval), and the four C-terminal helices, the CACTD (red oval). The N-terminal salt 
bridge is highlighted in stick view in white. Image adapted from PDB structure ID 3MGE 
[67]. 
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that signal CA to assemble into the mature capsid.  
Much of the structural work on CA has been done using HIV-1 proteins. An NMR 
solution structure of HIV-1 CANTD alone, including residues 1 – 151 of the CA protein 
was first determined by Gitti et al. and revealed for the first time the presence of the 
proline-mediated salt bridge [52]. This structure was closely followed by a crystal 
structure of a dimeric full-length HIV-1 CA in complex with a Fab fragment, but an 
ordered CACTD was not observed in the crystal and only the structure of CANTD was 
solved [53]. A structure of the dimeric HIV-1 CACTD encompassing residues 151 – 231 
of CA was determined to 1.7 Å resolution. The authors identified W184 and M185 residues 
as critical residues for dimerization and confirmed this finding using viral constructs, 
thereby validating the crystallographic dimer interface as one found in authentic virions 
[54]. The CACTD structure was later confirmed using an extended construct embodying 
residues 146 – 231, which dimerizes similarly to full-length CACTD [55]. The first full-
length structure of retroviral CA was determined using EIAV CA and confirmed multiple 
sequence alignments that predicted conservation among retroviral CA at the level of 
secondary structure [65]. This was followed by the unambiguous docking of known CA 
domain structures into a 9 Å cryo-crystallographic structure of full-length CA in the viral 
lattice [60]. The first non-lentiviral CA structure to be solved was RSV [56, 57, 59], 
revealing that conservation of CA structure may span all retroviral genera. MLV, MPMV, 
and JSRV CANTD structures were later solved as well [58, 61-63]. The first hexameric 
structure of CANTD was determined by Mortuza et al. using N-tropic MLV, reflecting the 
hexameric rings observed in the assembled capsid lattice [58]. Finally, an X-ray 
 18 
 
structure of the full-length CA in a cross-linked hexameric form was solved by Pornillos 
et al., fully revealing the atomic interactions that tie together the mature CA lattice [64].    
Although there is little amino acid conservation among retroviral structural 
proteins, a unique region of high sequence conservation named the MHR is found at the 
beginning of CACTD. The MHR spans approximately 20 amino acid residues, is found 
across all retroviruses except spumaviruses and has even been identified in 
retroelements. The structure of the MHR overlaps the extended strand at the N-
terminus of CACTD and most of the first helix of CACTD (eighth helix of CA) [55, 57]. The 
function of the MHR is unknown, but mutations in the MHR often abrogate viral 
infectivity and compromise assembly [68-71]. Recently, the MHR has been implicated in 
the formation of an inter-domain interface with the spacer region downstream of CACTD 
[30], suggesting that it may be involved in immature assembly.  
CACTD also contains a single buried but essential cysteine in alpharetroviruses, 
and a pair of cysteines in nearly all other orthoretroviruses [56] except 
gammaretroviruses. Mutation of the single cysteine (C192) in RSV wrecks assembly [72], 
but the residue is not reactive in intermolecular thiol cross-linking experiments [73], 
consistent with its being buried in the structure of CACTD. Therefore, C192 is preserved in 
the otherwise cysteine-free Gag constructs used in the cysteine cross-linking 
experiments described in this dissertation. 
NC domain 
The NC domain of Gag binds and protects the viral genomic RNA. NC is the 
smallest of the three canonical Gag domains and appears to be unstructured aside from 
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the presence of one or two “zinc fingers”, zinc-coordinated cysteine-rich structural motifs 
(CX2CX4HX4C) that bind specifically to a highly structured stem-loop-rich region located 
in the 5’ UTR of the viral genomic RNA known as Ψ, or psi [74]. Zinc fingers are 
characteristic of all retroviral NC domains except spumaviruses which lack the NC 
domain altogether [1], and different orthoretroviral species may have one or two zinc 
finger motifs. In RSV, both zinc fingers are not required for immature assembly, as the 
cysteines in the zinc fingers can be mutated to alanines and serines without 
compromising assembly [72, 75, 76]. The preference of the NC domain for psi binding is 
what directs the virus to specifically package genome-sized retroviral RNA, rather than 
the abundant cellular RNA and spliced retroviral RNA in the cytoplasm [74]. NC also 
carries a net positive charge that contributes to nucleic acid binding, and basic residues 
flanking and in between the two zinc fingers in both RSV and HIV-1 are required for psi 
binding [75, 77].  
It has been proposed that the initiating event in Gag assembly is driven by the 
binding of several molecules of Gag to the dimeric retroviral genomic RNA via their NC 
domains, and that this pre-formed complex binds to the PM and nucleates subsequent 
virion assembly [15, 78-80]. Using RSV Gag in an in vitro assembly system, Ma et al. 
showed that the shortest length of oligonucleotide required for efficient assembly of Gag 
is 16 nt, which provides enough binding space for two units of the NC domain. Thus, the 
lowest multimeric state required to trigger assembly is a dimer [79]. In fact, the NC 
domain of RSV and HIV-1 can be replaced by a leucine zipper dimerization domain and 
still support Gag assembly, validating the aforementioned conclusion [81-83].  
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Minor domains 
The minor cleaved domains of Gag differ significantly across retroviral species in 
their size and function. Among the best-understood are the minor domains of RSV, HIV-
1, MPMV and MLV Gag. The domain organization in RSV Gag is as follows: MA-p2-
p10-CA-SP-NC-PR (Figure 1.3). Both the p2 and p10 domains contain short amino acid 
motifs collectively known as late domains. Three classes of late domains are found in 
retroviruses with the following consensus sequences: PT/SAP, PPXY, and LYPXnL. 
These motifs each recruit distinct components from the cellular ESCRT machinery and 
at least one late domain is required for efficient retroviral budding. Late domain deletion 
mutants produce virus particles that remain tethered to the cell surface, unable to pinch 
off the membrane attachment that holds them to the PM [84]. In RSV, a PPPY motif is 
found in p2 and a LYPSL is located in p10. The p10 domain is also a “molecular switch” 
in Gag assembly, in that it promotes immature lattice formation by creating an interface 
that is not present in the mature capsid [72]. SP is the spacer peptide, located between 
CA and NC and is also a molecular switch hypothesized to form an ultrastructural 
element required for immature assembly. The role of SP in Gag assembly is the main 
focus of this thesis and will later be described in detail. PR is encoded as a domain of 
Gag by RSV, rather than as part of Gag-Pol like in most other retroviruses. 
HIV-1 Gag includes, from N- to C-terminus the following six domains: MA-CA-
SP1-NC-SP2-p6 (Figure 1.3). SP1 is hypothesized to play a similar role as RSV SP in 
promoting the structure of the immature core [9]. The role of SP2 is unclear, though it 
has been proposed to play a role in regulating the kinetics of Gag processing by PR 
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[85]. The p6 domain contains the late domain PTAP and a LXXLF motif that seems be 
homologous to the LYPXnL motif [86]. The p6 domain also binds Vpr, one of the six 
HIV-1 accessory proteins. Vpr plays a number of roles in the HIV-1 life cycle, including 
facilitating PIC nuclear entry, binding promoter regulating elements to increase HIV-1 
RNA production, and arresting the cell cycle at G2 to promote virus production [87].  
The domains of MPMV Gag are MA-pp24-p12-CA-NC-p4 (Figure 1.3). The pp24 
domain harbors the PPPY and PSAP late domains [88, 89] and contains a highly basic 
stretch of amino acids that may play a role in Gag localization to the nuclear pore and 
viral genome packaging [90]. Several studies have attempted to elucidate the role of the 
MPMV p12 domain in Gag assembly, and have characterized an internal scaffolding 
domain (ISD) believed to promote higher-level Gag oligomerization at low concentration 
[91-93]. The ISD appears to constitute a functional domain, as an HIV-1 Gag- MPMV 
p12 chimera can assemble in a reticulocyte system that is ordinarily restrictive to HIV-1 
Gag assembly, but permissive to MPMV Gag assembly [94]. Since MPMV assembles 
inside the cytoplasm rather than at the PM, it has been hypothesized that the ISD may 
be the mechanism by which MPMV overcomes the requirement for high Gag 
concentration for assembly, which is fulfilled by association with the PM in other 
retroviruses [91]. The function of the p4 domain is currently unknown. 
MLV Gag has a single minor cleavage product, p12, located between MA and CA 
(Figure 1.3). MLV p12 appears to be a multifunctional domain. It is a structural switch 
for immature assembly, similar to RSV p10, as deletion of p12 results in tubular, rather 
than spherical VLPs [95, 96]. The PPPY late domain is also found in MLV p12. In 
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addition, the p12 domain also plays an interesting and unique role in PIC trafficking. 
Certain mutations in p12 abolish viral infectivity, apparently by preventing the PIC from 
correctly localizing to the host cell nucleus [97, 98]. This phenotype is caused, at least in 
part, by disrupting p12-mediated attachment of the PIC to mitotic chromosomes, 
allowing the PIC to gain access to the nucleus during cell division [99, 100]. 
Gag conformation 
The conformation of Gag has been extensively explored by Datta et al., who 
have shown that in solution, monomeric Gag can exist in an elongated, linear 
conformation (MLV), similar to that found in assembled immature virions, or as a 
compact “horseshoe” structure (HIV-1) in which the MA and NC domains are near one 
another and Gag is folded over at one of its flexible regions (HIV-1) [101, 102]. The 
significance of the folded-over monomer is a matter of active study, as HIV-1 Gag must 
take on its elongated conformation before immature assembly can be possible. It has 
been suggested that this conformational change may reflect an additional regulatory 
step in Gag assembly, as HIV-1 Gag must simultaneously bind membrane and nucleic 
acid before taking on a linear conformation favorable for protein-protein interactions that 
drive oligomerization [103]. Interestingly, HIV-1 Gag on its own fails to assemble in vitro 
into VLPs resembling bona fide virions. However, upon addition of inositol 
pentakisphosphate (IP5) or inositol hexaphosphate (IP6) derivatives which are highly 
negatively-charged molecules, correct VLP assembly can be induced [16, 104]. These 
findings suggest that the folded-over conformation of Gag may prevent premature 
assembly within the cytoplasm prior to an electrostatics-mediated release.  
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RETROVIRAL CORE ARCHITECTURE 
Stoichiometry of assembly 
The number of Gag proteins required to assemble an immature core has been 
studied in detail using RSV and HIV-1. Using RSV, Vogt and Simon were the first to 
employ scanning TEM to measure the mass of purified viral particles. After making 
assumptions for the percentage of lipids, RNA, and carbohydrate from the glycosylated 
Env, and contaminating vesicles, the authors estimated that 73% of the total viral 
protein is Gag, which corresponds to approximately 1500 Gag molecules per virion 
[105]. This number was adjusted downward to 1200 in a different scanning TEM study 
[76], then adjusted upward following a later cryo-EM study, which measured lattice 
spacing between hexamers and the radius of the virions to calculate the number of Gag 
proteins per virion, which is approximately 2500 [106]. In HIV-1, the number of Gag 
proteins required for an immature core is much higher, at 5000 molecules per virion as 
measured by cryo-EM. This difference between the two viruses was attributed to the 
smaller size of RSV VLPs. However, these calculations are based on the assumption 
that the immature core forms a complete sphere. Since Wright et al. first discovered that 
the core lattice in immature virions harvested from cells is only, on average, 40% 
complete in HIV-1, a follow-up study by de Marco et al. found that this feature is 
conserved among retroviruses [9, 107]. Therefore, the actual number of Gag molecules 
may be much lower than the values calculated by lattice spacing and virion size. 
Interestingly, mature HIV-1 capsids have been estimated to contain no more than 
1250 units of CA [108, 109]. Even considering the incomplete Gag lattice, this number is 
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significantly lower than 40% of the estimated 5000 Gag molecules in immature HIV-1 
cores. The substantial difference in the number of proteins required to assemble an 
immature or mature core led to the hypothesis that at least in HIV-1, the virus 
disassembles the immature core following proteolytic cleavage and reassembles the 
capsid, and does not simply rearrange protein-protein contacts in the immature lattice to 
transform it into a mature lattice [10]. Not all of the liberated CA is used to assemble the 
mature capsid, as measurements performed on capsid assemblies using hydrogen-
deuterium exchange (HDX) coupled with mass spectrometry (MS) have shown that in 
mature assemblies, CA is present in both unassembled and assembled forms [110]. 
Mature CA capsid 
Ganser et al. first proposed that the mature CA capsid is organized based on the same 
underlying principles governing the structure of fullerene cones [111]. A fullerene cone 
is an elemental carbon structure built from a layer of hexameric carbon subunits that 
form a curved sheet. The cone is closed at the ends by the incorporation of 12 
pentameric “defects” into the hexameric sheet, based on the Euler characteristic. 
Similarly, a retroviral capsid can be made of hexameric and pentameric units of CA. 
Depending on where the pentamers are located in the viral capsid, the capsid takes on 
different geometries (Figure 1.5). For example, the vast majority of HIV-1 capsids 
incorporate five pentamers at the narrow end of the cone, and seven pentamers at the 
broad end [111]. Although other arrangements are possible, they result in altered capsid 
geometries. An even distribution of pentamers on both ends of a hexameric tube would 
result in a pill-shaped capsid, as observed in MPMV, while a scattered distribution of 
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pentamers over the hexameric lattice would result in a roughly spherical capsid, like that 
of MLV [112]. A preponderance of later data showed that the proposed fullerene capsid 
geometry is common to most retroviruses [108, 113-116] and reflects the lattice 
organization in both authentic virions as well as capsid assemblies [11, 109]. Once CA 
hexamers and pentamers were directly visualized using X-ray crystallography, the 
fullerene cone HIV-1 capsid was modeled in its entirety [116]. 
CA hexamers 
 The CA hexamer is the basic building block of the retroviral capsid (Figure 1.6). 
Early on, rings that appear roughly hexameric could be observed using TEM in stained 
virions. However, the existence of the CA hexamer was first confirmed by cryo-EM 
followed by image reconstruction of in vitro assembled CA tubes, which revealed a 
network of CA hexamers at 20 – 30 Å resolution [108]. The spacing between hexameric 
rings is 9.6 nm [109]. By fitting in the X-ray structures of the two domains of CA, it was 
determined that CANTD forms the bulk of the hexamer, while CACTD is located beneath 
the hexameric ring and links neighboring hexamers to one another. Using a novel 
technique combining cryo-EM and 2D crystallography, Ganser-Pornillos et al. were able 
to generate a higher resolution density map into which existing CANTD and CACTD 
structures could be docked unambiguously. This study validated three major interaction 
surfaces in the mature lattice. First, the CANTD-CANTD interface is the hexamerization 
interface, with helices 1, 2, and 3 interacting with neighboring CANTD subunits to form 
the central hole. This finding confirms alanine mutagenesis and HDX results that 
showed these helices to be critical for capsid assembly and protected from exchange  
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Figure 1.5: Retroviral capsids are fullerene cones. MLV, MPMV, and HIV-1 virions 
harvested from cells are shown above and differ obviously in capsid morphology (top). 
The fullerene cone model for each capsid morphology is shown as a network of 
hexameric rings (interconnected grey spheres) interspersed with pentameric defects 
(red). The location and distribution of pentamers determines the morphology of the 
fullerene cone (bottom). Figure adapted from Ganser-Pornillos et al. [112]. 
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Figure 1.6: Immature and mature hexamers differ in protein-protein contacts. The 
immature hexamer has a large central hole that is absent in the mature (A & B, top). 
The positioning of CACTD relative to the CANTD ring is lower in the immature hexamer 
than in the mature (A & B, bottom). The specific contacts that hold together the 
immature and mature hexamers also differ drastically (C). The cryo-EM densities of the 
immature and mature hexamers were based on data from HIV-1 virions, as modeled by 
Briggs et al. [8] and the table of putative contacts was based on a cryo-EM model of 
MPMV tubes, as modeled by Bharat et al. [117]  
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when assembled [112, 118, 119]. Second, the CACTD-CACTDinterface mediates mature 
lattice formation by dimerizing interactions in helix 9, as previously uncovered in an X-
ray structure of HIV-1 CACTD [54, 55]. The dimers tie two adjacent hexamers together, 
resulting in lattice formation. Third, a CANTD-CACTD interface formed by helices 4, 8, 9, 
10, and 11 mediates interactions between adjacent CA molecules within the hexamer, 
confirming a previous prediction made by Lanman et al. using chemical cross-linking 
and HDX [110, 118].  
The atomic-level structure of the HIV-1 CA hexamer was finally solved by 
Pornillos et al. through elegantly placed mutations and thiol cross-linking guided by the 
lower resolution Ganser et al. structure. Two cysteine mutations were placed at 
positions 14 and 45 in the CA protein (A14C and E45C) to stabilize the CANTD-CANTD 
interactions that form the hexameric ring, while two alanine mutations were made to 
positions 184 and 185 in CA (W184A and M185A), disrupting the well-characterized 
lattice-forming dimerization interface. This engineered CA construct was cross-linked 
into soluble hexamers amenable to crystallization. The hexameric interface between 
CANTD subunits is highly solvated, suggesting a likely mechanism for the quasi-
equivalence between CA hexamers and pentamers (further discussed in the following 
section), as the water molecules in the hydrogen-bonding network can easily adapt to 
the altered protein conformations required for pentamer formation. The extensive 
CANTD-CACTD interface is also water-rich and possesses a network of intermolecular 
helix-capping interactions, whereby each helix in the CANTD-CACTD interaction surface is 
capped by another residue in the adjacent molecule [64]. A later cryo-EM study also 
revealed a novel CACTD-CACTD interaction at the local three-fold axis between three CA 
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hexamers mediated by neighboring CACTD dimers. Although the cryo-EM images were 
only reconstructed to 16 Å resolution, the putative interacting residues were confirmed 
using cysteine mutations and disulfide cross-linking [120]. 
These high-resolution structures of the CA hexamer have provided a model for 
the generation of curvature on the hexameric lattice, where flexibility in the CACTD layer 
can tilt the relatively rigid CANTD layer sufficiently to allow curvature, regardless of 
whether pentameric defects are introduced, while preserving the helix-capping 
interactions in the CANTD-CACTD interface [64, 121]. A study by Bailey et al. also showed 
that RSV CA has significantly fewer constraints in the CANTD-CACTD interaction surface, 
suggesting a possible mechanism for the formation of different core morphologies [121].  
CA pentamers 
 Based on the fullerene geometry hypothesis, closure of the mature capsid 
requires incorporation of 12 pentameric defects, which had been inferred to exist since 
the fullerene cone hypothesis was first proposed [111]. However, it was not until 
recently that pentamers were directly visualized by Cardone et al. in cryo-EM 
reconstructed RSV capsid assemblies. RSV CA was induced to assemble into small 17 
nm particles in 0.5 M phosphate buffer. These particles were reconstructed and found to 
be T = 1 containing 12 pentamers. Docking CA crystal structures into the cryo-EM 
densities revealed that CA pentamers and hexamers are quasi-equivalent, meaning that 
the formation of a pentamer required only the removal of one subunit from the hexamer, 
and that the molecular interactions in both pentamers and hexamers are similar (Figure 
1.7) [113]. Hyun et al. later produced RSV T = 1 icosahedral capsid assemblies using 
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low pH rather than phosphate buffer to trigger assembly and confirmed that these were 
also the product of 12 CA pentamers [122]. The observation of icosahedral VLPs is 
unique to RSV, and although icosahedral capsid assemblies do not reflect authentic 
retroviral capsid assembly, they allowed the direct visualization of CA pentamers and 
confirmed the fullerene cone hypothesis for capsid assembly. Structural conservation of 
the CA pentamer among different retroviruses was confirmed by Pornillos et al., who 
used a thiol cross-linking technique similar to that used for CA hexamers to solve the 
structure of the HIV-1 CA pentamer [116].  
Immature Gag core 
Unlike the mature capsid which differs significantly in morphology across retroviral 
species, the immature Gag core has a more uniform spherical appearance [107]. Based 
on cryo-EM and image reconstruction, the immature core lattice is made up entirely of 
Gag hexamers. The lattice is continuous, but incomplete, as regions lacking protein 
density are clearly visible beneath the membrane layer (Figure 1.8) [8]. The incomplete 
core allows for curvature in the purely hexameric lattice, overcoming the requirement for 
the incorporation of pentamers to close the core. This observation provides a simple 
explanation for the relatively uniform appearance of immature retroviral cores. An 
incomplete core also fits into the retroviral life cycle, as the necessary proteins for viral 
maturation and subsequent steps are incorporated into the virion as part of the 
structural polyprotein, and the viral genomic RNA also enters the nascent virion via 
Gag-binding. Core closure is only necessary during maturation, so that the virus may 
enclose all of the required components for a new round of infection. 
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Figure 1.7: Pentamer and hexamers of mature CA are quasi-equivalent. A) The 
HIV-1 pentamer (left) and hexamer (right) are shown. The α-helices are represented as 
rods, with the locations of the thiol cross-linkages that stabilized the pentamers and 
hexamers for crystallography highlighted in yellow. B) The pentamer and hexamer are 
shown in cartoon representation. C) The quasi-equivalence of the pentamer and 
hexamer is shown. A simple change in the angle between interacting surfaces explains 
the shift between pentamer and hexamer assembly. Figure adapted from Pornillos et al. 
[116].  
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Figure 1.8: The immature core of retroviruses is made of an incomplete lattice of 
Gag hexamers. A. Three representative HIV-1 virions are shown above. The 
incomplete immature core layer is visible under the complete membrane layer. B. Each 
sphere represents a VLP that was reconstructed based on cryo-EM tomography and 
sub-tomographic averaging. Hexamers are colored based on the calculated cross-
correlation and the confidence of each hexamer assignment ranges from red (low 
confidence) to green (high confidence).  Figure adapted from Briggs et al. and de Marco 
et al. [8, 107].  
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Gag hexamers 
Although the mature hexamer consists of proteolytically processed CA and the 
immature hexamers are primarily composed of the CA domain of Gag, respectively, 
structural constraints present in the CA domain but absent in proteolytically processed 
CA create an immature hexamer that is substantially different from the mature. Even 
when observed at low resolution, using cryo-EM reconstruction, there are several 
notable differences between the two hexamers that led to the inference that the mature 
and immature hexamers differ in specific protein-protein contacts (Figure 1.6). The 
observed differences include the following. The Gag hexamers have a large central hole 
absent from CA hexamers. The orientation of CANTD subunits that make up each Gag 
hexamer differs from that found in the CA hexamer. The CACTD layer is located further 
beneath the CANTD layer in Gag hexamers and is entirely tucked beneath the CANTD 
layer, while the CACTD layer in CA hexamers forms a ring around the CANTD layer just 
beneath it [8, 9]. The spacing between each immature hexamer is also smaller, 
measuring 8.0 nm rather than 9.6 nm, as found in the mature hexamer [10]. One 
interaction between the p10 and CA domains of RSV Gag was found to favor immature 
hexamer formation by creating an interface that pries apart the hexamer, providing a 
putative mechanism for the formation of the large central hole in the immature hexamer, 
but absent in the mature (Figure 1.9) [72]. The SP1 domain of HIV-1 Gag has also been 
proposed to play a similar structural role in promoting immature interactions in the CA 
domain [9], which will be further discussed in the following section.  
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A recently published study using cryo-EM tomography and crystal structure 
docking by Bharat et al. took advantage of the helical symmetry found in MPMV tubes 
to build an 8 Å model of the immature lattice. This model revealed some key distinctions 
between protein contacts found in the immature and mature cores, most notable being 
that contacts between adjacent CANTD subunits form dimeric inter-hexamer interfaces, 
rather than intra-hexamer interfaces, while the only contacts that appear to hold 
together the hexamer are located in CACTD.  Also, the extensive CANTD-CACTD interface 
found in the CA hexamer is not present in the Gag hexamer. Another interesting 
comparison is the number of residues involved in intra-hexamer contacts. In the mature 
hexamer, the total number of residues that form contacts in the hexamer is 43, while it is 
only five in the immature hexamer (Figure 1.6) [117]. This discrepancy in the number of 
contacts suggests that, as is the case with RSV p10, other domains flanking CA may be 
involved in forming contacts that promote the immature hexamer. A prime candidate to 
fulfill this role, at least in RSV and HIV-1, is the downstream spacer peptide SP. 
SP in the immature hexamer 
The spacer peptide is a minor cleavage product of Gag in alpharetroviruses and 
lentiviruses. In RSV Gag, it is known as the SP domain and is located immediately 
downstream of CA, while in HIV-1, the homologous peptide is called SP1. Kräusslich et 
al. were the first to propose that HIV-1 SP1 may play a part in forming a transient 
assembly domain with HIV-1 CACTD that results in a critical intermolecular interaction 
during immature assembly [123]. This hypothesis was further extended by Accola et al., 
who proposed that the disruption of a helix spanning the HIV-1 CA-SP1 junction is  
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Figure 1.9: The RSV p10 domain forms an intermolecular interface between Gag 
molecules. A. Three CANTD subunits that make up the immature hexamer are shown in 
space-fill model, while the other three subunits are in ribbon model superimposed over 
space-fill. The p10 domain of one subunit forms intermolecular interactions with helices 
1 and 2, and intramolecular interactions with helices 1 and 3 of the neighboring subunit. 
B. Cartoon representation of inter-hexameric interactions modeled based on the 
crystallographic dimer by Nandhagopal et al. [59]. The p10 domain is predicted to 
interact with residues that form part of the hairpin loop created by the N-terminal salt 
bridge in PR cleaved CA. Figure adapted from Phillips et al. [72]. 
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required for proper mature assembly [124]. Later studies using cryo-EM tomography 
reconstructions of immature RSV and HIV-1 VLP lattices revealed a pillar-like density 
located at the center of each immature hexamer below the densities assigned to CACTD 
(Figure 1.10) [9, 107]. This pillar-like density was originally hypothesized by Wright et al. 
to consist of a six-helix bundle (6HB) that contributes to the stability of an immature Gag 
hexamer [9]. For both RSV and HIV-1, secondary structure predictions assign amino 
acids including and immediately flanking the spacer peptide domain as a single 
amphipathic helix [107, 124-126]. This structural prediction is not restricted to 
alpharetroviruses and lentiviruses. In gammaretroviruses, a highly charged region at the 
very end of CA has also been inferred to form an alpha helix [127], though there is no 
cleaved spacer peptide. Amino acids in this region can be deleted without affecting MLV 
Gag assembly, as long as the deletions allow conservation of the original helical phase.  
The NMR structure of a peptide corresponding to HIV-1 SP1 and eight adjoining 
amino acids shows that this region has the ability to form an amphipathic helix under 
certain conditions, though the biological relevance of this structure has been questioned 
as it was solved in the presence of 30% trifluoroethanol (TFE), a helix-promoting solvent 
[125]. A more recent study using a different HIV-1 peptide encompassing the last eight 
amino acids of CA and the N-terminal two-thirds of SP1 showed a shift in the circular 
dichroism (CD) spectrum from unstructured to α-helix when peptide concentration was 
increased to levels comparable with the local protein concentration in an authentic 
assembling virion. This finding was interpreted to mean that SP1 acts as a 
conformational switch that shifts between two states, remaining mostly unstructured 
until virion assembly increases the local concentration of Gag, at which point SP1 
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Figure 1.10: SP forms a pillar beneath the organized CA lattice in authentic 
virions and VLPs. Reconstructed electron densities obtained from cryo-EM 
tomography of authentic immature HIV-1 virions are shown on the left. The densities 
assigned to CANTD are shown in blue, those assigned to CACTD are shown in yellow, and 
the pillar-like density below was assigned to the putative SP1 domain helical bundle. A 
tomographic slice of an RSV VLP is shown on the right. Electron dense areas are white, 
while areas without electron density are black. The densities assigned to one unit of 
Gag are highlighted (CANTD in blue, CACTD in yellow, and SP in purple). Figure adapted 
from Wright et al. and de Marco et al. [9, 107]. 
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adopts a more helical conformation to provide interaction surfaces for the assembling 
immature virion [102]. Our lab defined a similar critical region for immature assembly in 
RSV, starting just downstream of the structured CACTD and extending into SP [126]. 
Although RSV SPA and HIV-1 SP1 share little sequence homology, their proposed role 
as a molecular switch in stabilizing the immature hexamer is likely to be similar. 
RETROVIRAL ASSEMBLY 
Assembly in cells 
Gag is the only protein required for the production of VLPs in cells. When 
transfected into cells, expression of Gag results in the production of VLPs that are 
physically indistinguishable from virions produced by infected cells. The fact that Gag is 
both necessary and sufficient for VLP assembly provides a means to study individual 
steps in immature retroviral assembly and maturation, which is often accomplished by 
introducing mutations in Gag and observing their effects on different steps in the 
immature assembly and maturation processes. For example, mutations that affect the 
curvature of the viral core lattice result in the accumulation of flat or dome-shaped 
sheets of Gag at the PM and can be easily visualized using thin-section TEM [128]. 
Another striking example comes from late domain deletion mutants, where the 
expression of these mutant Gag results in tethered VLPs and gives the surface of the 
transfected cell a blistered appearance when examined by scanning EM. Gag assembly 
in cells is a useful technique in the study of the late steps of the retroviral life cycle and 
Gag interactions with different cellular factors and components.  
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However, specific Gag-Gag and CA-CA interactions that drive self-assembly of 
retroviral cores are more difficult to tease out using cell-mediated Gag assembly. It is 
challenging to determine whether a mutant phenotype is the result of a disruption of 
bona fide Gag-Gag interactions, or the interaction between cellular factors and Gag. 
Conversely, if mutations lead to a wild-type immature assembly phenotype, it cannot be 
concluded that the mutation has no effect on immature assembly. In order to study both 
immature and mature assemblies at the molecular level, a better, more well-defined 
system was required, resulting in several groups independently developing in vitro VLP 
and capsid self-assembly systems.  
General in vitro assembly 
Much of the current knowledge on retroviral assembly emerged as a result of the 
development of in vitro assembly systems. These systems use purified retroviral 
structural proteins derived from Gag or CA to recapitulate immature and mature viral 
assembly in a cell-free environment. The resulting VLPs are identical to authentic 
virions when assessed using cryo-EM and radial density measurements [10]. Immature 
in vitro assembly using Gag or Gag-derived proteins generally results in the production 
of spherical VLPs similar in morphology to immature virions, although MPMV is a 
notable exception, as immature MPMV assembly can produce tubes as well as spheres, 
both with an immature Gag lattice. Capsid assemblies differ somewhat from bona fide 
retroviral capsids, but appear to maintain the same lattice organization. Mature in vitro 
assembly using CA generates capsid assemblies of various morphologies, including 
cones, tubes, or polyhedral structures under specific pH and salt conditions. VLPs and 
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capsid assemblies can be easily purified by centrifugation and visualized using 
negative-stain EM. Given the high degree of similarity between in vitro assembled VLPs 
and authentic virions, in vitro assembly has been used extensively to tease apart the 
protein-protein interaction involved in self-assembly. Currently, in vitro assembly is well 
established using Gag-derived and CA proteins from three model retroviruses: HIV-1, 
MPMV, and RSV, each of which will be described in detail in the following sections. 
HIV-1 in vitro assembly 
The first reported retroviral in vitro assembly used HIV-1 CA. Knowing that plant 
virus capsids, including that of tobacco mosaic virus, can self-assemble in vitro, Ehrlich 
et al. examined purified CA protein using negative stain EM. They noticed that the 
protein appeared to form branching fibrous structures approximately 200 nm in length 
as well as smaller spheres and rods. Using a high concentration of CA (10 mg/mL), the 
purified protein was dialyzed against various pH and salt conditions and it was found 
that HIV-1 CA assembles into structured tubes in acidic buffer with high salt (acetate 
buffer pH 6, 1.0 M NaCl) [129]. Tubular capsid assemblies have the same lattice 
organization as authentic mature virions and are inferred to represent a mature-like 
lattice in in vitro assembly, except in the case of MPMV [108, 109, 117].  
The optimal conditions required for CA purification and in vitro capsid assembly 
were later defined by Gross et al., who showed that CA assembles most efficiently in 
alkaline high salt buffer (1M NaCl, pH 8.0) and at higher protein concentrations (4 
mg/mL) [130]. Gross et al. also reported that a five amino acid N-terminal extension of 
CA is sufficient to convert the particle phenotype from tubular to spherical. The spherical 
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particles reported in this study did not have the electron-lucent hole observed in 
authentic immature virions and are likely some aberrant form of assembly. However, the 
observation led to the proposal that formation of the N-terminal salt bridge is essential 
for tubular assembly and, by inference, for the assembly of the immature lattice [131]. 
Immature HIV-1 assembly was shown for the first time by Campbell and Rein, 
who used an HIV-1 Gag lacking the C-terminal p6 domain to generate small spherical 
VLPs approximately 25 – 30 nm in diameter in high pH (pH 8.0) and low salt buffer (0.1 
M NaCl) in the presence of RNA [104]. As authentic HIV-1 virions are normally 100 – 
120 nm in diameter, these VLPs were obviously defective at some step in assembly. 
Campbell et al. later determined that binding to IP5 and other inositol phosphate 
derivatives can trigger HIV-1 Gag assembly into VLPs of the correct diameter, and they 
isolated the region of Gag that binds to IP5 to amino acids 16 – 99 [16]. As discussed 
above, HIV-1 Gag assembly may be regulated through conformational changes in the 
Gag monomer [102]. Therefore, binding to IP5 may render the Gag monomer available 
for higher order oligomerization by releasing Gag from its horseshoe conformation into 
the assembly-ready extended conformation. 
MPMV in vitro assembly 
The MPMV in vitro assembly system was initially developed by Klikova et al., 
who were the first to show that immature assembly can also be recapitulated in vitro 
and who provided the first evidence that in vitro assembled particles have the same 
protein-protein interactions as virions collected from infected cells. They denatured the 
Gag protein found in inclusion bodies using 8 M urea and restored its function by 
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controlled dialysis. In basic Tris buffer (pH 8.8), approximately 50% of the Gag protein 
had changed from fully soluble to pelletable by centrifugation. The pelleted sample was 
run through a sucrose gradient and the majority of pelleted Gag was found in the 
fraction corresponding to a density of 1.19 g/mL. When this fraction was visually 
examined using negative-stain EM, spherical particles with an electron-dense ring 
surrounding an electron-lucent core were observed [132]. This morphology was very 
similar to immature betaretrovirus particles collected from infected cells [133], 
suggesting that in vitro assembled VLPs form via the same mechanisms that drive 
authentic immature assembly.  
Since authentic MPMV Gag virions assemble in the cytoplasm, upon Gag 
expression in E. coli, assembled VLPs are abundantly observed in inclusion bodies. The 
morphology of these intracellular VLPs mimic in vitro assembled VLPs and the 
technique is often used to assess MPMV assembly phenotypes. Using the E. coli 
mediated assembly system, CA alone does not form any observable capsid assemblies, 
suggesting that the MPMV mature assembly pathway may differ fundamentally from 
that of HIV-1 and RSV [134]. However, a purified MPMV CA-NC construct lacking the 
N-terminal proline (Pro(-)CA-NC) can assemble in vitro into both tubes and spheres 
[117, 135], and this result can be recapitulated using the intracellular E. coli assembly 
system [134]. Since isolated MPMV virions have capped cylindrical capsids, it was 
initially believed that, as for HIV-1, tubular MPMV assembly reflects mature assembly, 
but the recent cryo-EM study by Bharat et al. showed that, despite their morphology, 
Pro(-)CA-NC tubes actually have an immature lattice [117].  
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RSV in vitro assembly 
Campbell and Vogt worked out the first RSV in vitro assembly system using a 
Gag-derived protein containing the CA-NC region. CA-NC can assemble into irregular 
spherical particles when a concentrated sample of the protein (10 mg/mL) is dialyzed 
into acidic buffer (pH 5.5). However, upon addition of RNA, CA-NC (pH 5.5) and the 
HIV-1 Gag-derived CA-NC-p6 (pH 8.0) assembled into tubes with a constant diameter 
of 30 nm or 50 nm, respectively. In the presence of RNA, these constructs assembled 
more efficiently than purified protein alone, requiring only 1 mg/mL of protein instead of 
10 mg/mL. This was the first study to show that nucleic acid plays an important 
structural role in retroviral assembly by enhancing the efficiency of assembly [15]. 
Campbell and Vogt also developed a highly robust immature assembly system using a 
Gag construct lacking the MBD of MA and the PR domain, henceforth referred to as 
ΔMBDΔPR. This protein is easily and abundantly purified from E. coli, as it remains in 
the soluble fraction of the cell lysate and can be separated from most cellular proteins 
by charge, using the positive charges in NC. ΔMBDΔPR assembles optimally in slightly 
acidic conditions (pH 6.5) at low salt concentration (0.1 M NaCl) with approximately 
10% wt/wt nucleic acid [13]. 
A system for RSV capsid assembly was first described by Purdy et al. to study 
the role of the MHR [71]. CA was discovered to assemble at a concentration of 2 mg/mL 
in the presence of 0.5 M sodium phosphate. It was found that capsid assembly involves 
a lag time that can be shortened by increasing CA concentration, increasing buffer pH, 
or by changing the type of buffer, with sodium phosphate dibasic being the most 
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favorable for assembly [136]. The authors took this finding to mean that capsid 
assembly requires nucleation, specifically the formation of CA protein dimers. Aside 
from assembling into particles that resemble authentic capsids, CA assembly in vitro 
also generated small icosahedral particles that allowed for CA pentamers to be 
visualized for the first time [113].  
THESIS OUTLINE 
 In this dissertation, I will discuss my work which centers on the structural 
contribution of the SPA domain to immature assembly. Chapter two outlines the 
materials and methods used to perform the experiments described in this dissertation. 
Chapter three first addresses the structure of SPA using mutations coupled with in vitro 
assembly as the readout. Secondary structure prediction algorithms assign a high 
helical propensity to the SPA domain. When individual residues were mutated to 
alanine, in vitro assembly was abrogated with a majority of the mutated proteins, but not 
all of them. The locations of the tolerated mutations suggested that the predicted SPA 
helix may form a higher-order structure in the assembled VLP, and this hypothesis was 
strongly supported by HDX data generated by my collaborators in the Prevelige lab at 
the University of Alabama at Birmingham. I followed up on the SPA region by 
performing CD analyses on a peptide that covers the SPA domain and showed that it 
became more structured with increasing concentration, supporting our hypothesis that 
the SP region is unstructured in the Gag monomer, but becomes structured in the 
assembling VLP. The peptide was found to associate as a hexamer when analyzed by 
sedimentation velocity, again by our collaborators in the Prevelige Lab. These data 
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support the hypothesis that SP forms a six-helix bundle that ties together the immature 
hexamer.  
Chapter four describes the various protein constructs that I used in my attempts 
to crystallize the immature RSV core, as well as my ongoing efforts to obtain a crystal 
structure of the SPA crystal. I showed in this chapter that despite the inherent flexibility 
in the two-domain CA and its flanking sequences in Gag, it is possible to crystallize a 
protein spanning the minimal regions required for immature assembly. I also crystallized 
the SPA peptide, but the crystals proved to be of insufficient quality for diffraction. 
Finally, chapter five consists of a discussion of the contribution of in vitro assembly to 
the study of retroviral assembly, the implication of molecular switches in assembly, and 
some future experiments of relevance to the projects presented in this dissertation.  
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CHAPTER TWO 
MATERIALS AND METHODS 
DNA constructs for SP mutation analyses 
All alanine point mutations and insertion/substitution mutations were made using 
site-directed mutagenesis and the previously described ΔMBD.ΔBlpI.pET3xc construct 
[72], which was derived from the ΔMBD.pET3xc plasmid [13]. The mutations D472A/C – 
I475A/C were made by replacing the BlpI – SacII fragment of ΔMBD.ΔBlpI.pET3xc with 
the products of site-directed mutagenesis. A476S/C – A478S/C were made by replacing 
the BlpI – KpnI fragment, while M479A/C – N492A/C were made by replacing the SacII – 
KpnI fragment.  
The insertion mutant 3Ala was made by replacing the BlpI/SacII fragment with 
the product of site-directed mutagenesis. 7Ala1 was made using a version of 
ΔMBD.ΔBlpI.pET3xc containing a MluI site after the first four residues of the NC 
domain. The plasmid was digested using MluI and double-stranded oligonucleotides 
coding for seven alanines and containing the appropriate sticky ends were ligated in. 
7Ala2 and 7AA were made by replacing the SacII/KpnI fragment with the products of 
site-directed mutagenesis. The substitution mutant CMV1 was made by replacing the 
BlpI/KpnI fragment, CMV2 and SP1ins were made by replacing the SacII/KpnI fragment, 
and SP1sub was made by replacing the BlpI/SacII fragment. 
All cysteine point mutations were made in the same manner as described for 
alanine mutations, but used the ΔMBD.ΔBlpI (-11C) pET3xc plasmid as PCR template 
and vector backbone. All PCR products were amplified using ΔMBD.ΔBlpI.pET3xc as 
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the template. All final constructs used for protein expression were confirmed by 
sequencing. 
DNA constructs for “minimal Gag” constructs 
 SUMO-25CASP was made using ΔMBD.ΔBlpI.pET3xc as the PCR template, an 
upstream mutagenic primer that included a BamHI site, and a downstream mutagenic 
primer containing a HindIII site. The PCR fragment included the 25 required residues 
from p10, all of CA, all of SP, and the first four residues of NC. Using BamHI and 
HindIII, the PCR fragment was inserted into a digested pSUMO backbone immediately 
downstream of the SUMO tag. SUMO-25CASP(CC) was made in the same way as 
25CASP, but the ΔMBD.ΔBlpI (-11C) pET3xc construct containing the E51C/T20C 
mutation was used as the PCR template [72]. SUMO-Ccmk2-25CASP was made using 
25CASP.pSUMO as the backbone and a Ccmk2 PCR fragment containing a BamHI site 
at the N-terminus and an EagI site at the C-terminus was generated using a 
Ccmk2.pET22b plasmid (generously shared by Todd Yeates) as vector and two 
mutagenic PCR primers containing the aforementioned restriction sites [137]. All final 
constructs used for protein expression were verified by sequencing. 
Protein expression and purification using pET3xc vector 
All ΔMBDΔPR-derived mutants were expressed in E. coli BL21 cells. For each 
protein, 500 mL of culture was grown to log phase and induced using 0.5 mM IPTG for 
4 hours at 37ºC. Cells were pelleted by centrifugation in a Sorvall GSA rotor and 
resuspended in 25 mL high salt buffer (20 mM Tris, pH 8.0, 500 mM NaCl) containing 
10 mM DTT, 1 mM PMSF, and 20 µM ZnCl2, lysed by sonication and the lysate was 
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spun at 45,000 rpm for 3 hours using a Beckman Ti50.2 rotor to spin down ribosomes. 
ΔMBDΔPR and mutants are mostly found over-expressed in the supernatant. The over-
expressed proteins were first precipitated using saturated ammonium sulfate to a final 
concentration range of 25% to 30%, and spun at 9000 rpm for 10 minutes using a 
Sorvall SA-600 rotor to spin down the precipitated protein. The pellet was then 
resuspended in 10 mL low salt buffer (20 mM Tris, pH 8.0, 100 mM NaCl), filtered by 
syringe (0.45 µm pore), and further purified using a 1 mL cation exchange column 
(Amersham SP) mounted to an ÄKTA prime FPLC pump (Pharmacia Amersham). The 
protein was bound to the column with low salt buffer at a rate of 1.0 mL/minute, the 
column was washed with 10 mL low salt buffer, and the protein was eluted as a single 
fraction with high salt buffer. Concentrations of the purified proteins were determined by 
spectrophotometric measurements (260/280 nm) using either a Pharmacia Biotech 
Ultrospec 2000 or a Thermo Scientific NanoDrop 2000. 
Protein expression and purification using pSUMO vector 
 All SUMO-linked proteins were expressed in E. coli BL21 cells. For each protein, 
1 L of culture was grown to log phase and induced using 0.5 mM IPTG for 4 hours at 
30ºC. Cells were pelleted by centrifugation in a Sorvall GSA rotor and resuspended in 
50 mL binding buffer (50 mM Na2HPO4, pH 8.0, 1 M NaCl), lysed by sonication, and 
the lysate was spun at 9000 rpm for 30 minutes using a Sorvall SA-600 rotor. The 
supernatant was bound to 1 mL of Ni-NTA beads (QIAGEN Ni-NTA agarose beads, 
approximately 2 mL of bead slurry) for a minimum of 4 hours (up to overnight) at 4 ºC 
while gently rocking. The mixture was poured onto a chromatography column and the 
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beads were allowed to settle. The lysate was allowed to flow through at a rate of 
approximately 1 mL/minute and was collected for later analysis. The beads were 
washed using 20 mL wash buffer (50 mM Na2HPO4, pH 8.0, 1 M NaCl, 10 mM 
imidazole), also at a rate of 1 mL/minute, and the SUMO-tagged protein was eluted 
from the beads using 5 – 10 bead volumes of elution buffer (50 mM Na2HPO4, pH 8.0, 
1 M NaCl, 250 mM imidazole). 
In vitro assembly and EM 
When protein concentrations were equal to or above 5 mg/mL, the protein was 
assembled by dilution to 1 mg/mL in 50 mM MES, pH 6.5 after additions of 10% wt/wt of 
the ssDNA GT50 (a 50mer oligonucleotide composed of 25 GT repeats). Assembly 
reactions were complete after incubating at room temperature for 15 minutes. When 
protein concentration was below 5 mg/mL, assembly was performed by first diluting the 
protein to 1 mg/mL in 50 mM MES, 100 mM NaCl, pH 6.5. GT50 was added (10% 
wt/wt) and 50 µL of the protein-oligonucleotide mix was dialyzed overnight at 4ºC 
against 50 mM MES, 100 mM NaCl, pH 6.5.  Ten microliters of each assembly reaction 
was spotted onto a carbon-Formvar-coated copper grid for one minute, and then 
stained using a 2% uranyl acetate solution for one minute. The samples were examined 
using a Morgagni 268 transmission electron microscope. 
SPApep sequence and circular dichroism 
 The 28 or 29 amino acid SPApep, which encompasses residues P469 – D496 of 
RSV Gag with or without an exogeneous cysteine was purchased from the Tufts 
University Core Facility  (http://www.tucf.org/peptidesynthesis-f.html). The peptide was 
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synthesized using FastMoc Chemistry on an ABI 431 Peptide Synthesizer and further 
purified by HPLC. For TFE-dependent structural studies, the purified, lyophilized peptide 
was re-suspended in distilled H2O to a concentration of 10 mg/mL. Peptide 
concentration was calculated by measuring absorbance at 205 nm and using an 
extinction coefficient of 31 for 1 mg/mL [138]. SPApep was diluted into 10 mM sodium 
phosphate buffer, pH 6.5, 0 – 30% TFE just prior to recording the CD spectrum. Data 
were collected in the region of 190 – 250 nm with a 1 mm path length Hellma quartz cell 
and an AVIV 202 CD spectrometer (25ºC, 1 nm wavelength step, 10 s averaging time). 
For concentration-dependent studies in aqueous buffer, SPApep was diluted into buffer 
without TFE and measured as described above. For CD measurements at high peptide 
concentrations (10 mg/mL), a shorter path length (0.1 mm) quartz cell was used. 
The percent helicity was calculated using an Excel version of PEPFIT, 
generously provided by Michael Amon [139, 140]. For each CD spectrum, the best fit 
was obtained by selecting a counter setting of 4 for the initial round of analysis and 
eliminating reference curves that do not contribute to the spectrum. A second round of 
fitting was performed using a counter setting of 1. For each peptide concentration, the 
percent α-helix value was taken from the best fit. 
Modeling the 6HB using Swiss PDB Viewer 
The model was built using Swiss PDB Viewer. The raw amino acid sequence of 
the 28 residue SPApep (without the exogenous cysteine) was imported into Swiss PDB 
Viewer. The program automatically assigned residues L470 – R495 as α-helical and 
showed SPApep as a single helix. SPApep helix was spatially aligned with each 
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individual chain of CChex (PDB ID 3R3K) using the Magic Fit tool and the alignments 
were manually adjusted using the Clustal Omega sequence homology. The six resulting 
SPApep helices were then combined and subjected to energy minimization three times 
to minimize side-chain clashes.    
VLP purification via centrifugation 
 In vitro assembled VLPs were purified for cryo-EM studies by centrifugation 
through a 10% - 60% sucrose gradient to equilibrium. The sucrose-containing solutions 
were prepared using assembly buffer (50 mM MES, pH 6.5, 100 mM NaCl) and stored 
at 4ºC. Gradients were built immediately before use in Beckman thinwall Ultra-clear 4 
mL centrifugation tubes. The overall volume pipetted into each tube was 3.6 mL. The 
volume of each gradient step was calculated to be (3.6 mL – assembly volume) divided 
by eight. VLP assemblies were layered above the sucrose gradient and spun in a 
Beckman SW60 rotor at 50,000 rpm for 3 hours. The VLP fraction formed a visible band 
that was collected manually (200 – 400 µL) after suctioning the sucrose solution layered 
above. The collected fraction was diluted into assembly buffer to a total of 3.6 mL 
(minimum of 1:5 dilution) and VLPs were pelleted by centrifugation in the SW60 rotor at 
50,000 rpm for 1 hour. The VLPs were then resuspended in roughly 50 µL assembly 
buffer. 
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CHAPTER THREE 
MUTATIONAL ANALYSIS OF THE RSV SP ASSEMBLY DOMAIN 
expanded from Bush et al. (2013), manuscript in preparation 
INTRODUCTION  
The orthoretroviral Gag protein self-associates to form the immature retroviral 
core during assembly. Gag is a polyprotein consisting of the major domains MA, CA, 
and NC and several minor domains that differ among retroviruses. During the late 
stages of the virus life cycle, retroviral particles bud from the infected cell and 
maturation takes place. The transition from the immature Gag core to the mature CA 
capsid is brought about by PR-mediated cleavage of Gag during or soon after budding. 
Proteolysis of Gag releases its constituent protein domains. The liberated CA protein 
then reassembles to form the shell of the mature capsid [10, 106].  
Both immature Gag assembly and mature CA assembly can be recapitulated in 
vitro using purified proteins. Mature in vitro capsid assembly has been established using 
purified CA protein from lentiviruses [129, 130] and alpharetroviruses [57, 71, 113, 141]. 
The products of mature assembly can take on a variety of morphologies, including 
cones (HIV-1), tubes (RSV, HIV-1) or smaller polyhedral structures (RSV) under specific 
pH and salt conditions. Although the tubes are not outwardly similar to mature capsids, 
they conserve the CA lattice observed in retroviral protein cores [108, 111]. Immature 
VLPs have been successfully assembled using purified Gag-derived proteins from 
members of the lentiviridae [10, 104, 131, 142-144], alpharetroviridae [13, 15, 76, 145, 
146] betaretroviridae [132, 134, 147], and gammaretroviridae [102, 148] genera. 
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Immature assembly usually yields spherical particles, with the exception of MPMV, 
which is able to form tubes under certain conditions [117, 149]. VLPs formed by in vitro 
assembly are structurally comparable to virions collected from infected cells [8, 10, 106, 
111, 150, 151], lacking only the viral membrane.   
The immature Gag viral core and the mature CA capsid have a similar protein 
lattice composed of hexameric subunits.  The immature Gag lattice curves into an 
incomplete sphere in the immature viral core [8, 14, 107], while the mature CA lattice 
closes into a fullerene structure by incorporating 12 pentameric CA subunits into the 
mature lattice [108, 111-113].  In both the immature and mature lattices, the two 
independently-folding domains of CA, the CANTD and the CACTD, are the main 
constituents of both the pentameric and hexameric lattice subunits [9, 60, 107, 113, 
116, 117, 121]. Although the general lattice geometry is similar in immature and mature 
retroviral cores, the details of the CA lattice show several differences. These differences 
in protein-protein contacts in part result from intermolecular interactions that are absent 
in the cleaved CA protein. In the case of RSV, mutational studies in Gag including 
disulfide cross-linking followed by structural modeling showed that one such critical 
interaction takes place between p10, the domain immediately upstream of CA, and 
CANTD, and serves to stabilize the immature hexamer [13, 59, 72, 146].    
Another critical intermolecular interaction for immature assembly is found 
immediately downstream of the CA domain. In RSV, the cleaved SP is found in this 
region. Mutational studies have defined a 24 amino acid region including SP and 
flanking residues to be required for proper immature assembly, as insertion mutations in 
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this region result in tubular assembly [126]. By cryo-EM tomography, RSV VLPs show 
an organized hexameric lattice consisting chiefly of the CA domain, with periodic stalk-
like densities below the lattice [107]. I hypothesize that the structure underlying these 
densities is formed by amino acid residues immediately downstream of the folded CA, 
namely the last eight amino acids of CA, all of SP, and the first four residues of NC. I 
have named this region the SP assembly (SPA) domain, and I propose that neighboring 
SPA domains in a Gag hexamer coalesce to form a six-helix bundle (6HB).  
Using in vitro assembly, alanine scanning mutagenesis, and biophysical 
analyses, I have further characterized the structure and function of SPA. Most of the 
amino acid residues in SPA could not be mutated individually without abrogating 
assembly. I interpret these results to mean that the amino acids that do not tolerate 
mutations contribute to higher-order structures in VLPs. HDX analyses of unassembled 
Gag in comparison with assembled VLPs showed strong protection at the SPA region, 
consistent with a higher-order structure. Circular dichroism revealed that a 29mer SPA 
peptide shifts from a random coil to a helix in a concentration-dependent manner. 
Analytical ultracentrifugation (AUC) showed concentration-dependent self-association of 
the peptide into a hexamer. Taken together, these results provide strong evidence for 
the formation of a crucial 6HB in Gag assembly. 
RESULTS  
The RSV SP assembly domain is highly sensitive to alanine point mutations 
To guide structural studies of the RSV SPA domain, a string of amino acids 
including SP and adjoining sequences was submitted to PsiPred 
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(http://bioinf.cs.ucl.ac.uk/psipred/) for secondary structure prediction. Similar to 
previously reported results generated using an earlier version of PsiPred [126], 21 
residues, including the C-terminal five residues of CA, all of SP, and the N-terminal four 
residues of NC, were predicted to form an α-helix (Figure 3.1). I have termed this 
predicted structure the SPA helix. Although the region surrounding SP and its role in 
immature assembly have been studied previously using five- or two-amino acid insertion 
mutations coupled with baculovirus-mediated expression of Gag in insect cells [126], 
that study only defined the boundaries of the SPA domain and showed the entire 
domain to be indispensable for assembly.  
My interest is the structural contribution of the predicted SPA helix to the 
immature core. More specifically, I wanted to know if the SPA helix is able to form a 
6HB. To further probe the structural function of the SPA helix, I performed alanine 
scanning mutations on its 21 constituent residues (existing alanines were mutated to 
serines). Each mutant was made in a well-characterized, truncated version of Gag 
known as ΔMBDΔPR (Figure 3.1) that has been previously shown to assemble robustly 
in vitro and to form VLPs nearly identical to wild-type immature virions [13, 72, 76, 80, 
106]. The mutant proteins were expressed in E. coli, purified, and placed in assembly 
conditions in the presence of a long DNA oligonucleotide. Negative stain transmission 
electron microscopy (TEM) was used to evaluate the ability of the proteins to assemble. 
The mutants were scored as either positive or negative for assembly based on the 
presence or absence of VLPs, and each protein purification and assembly was 
performed at least twice. Table 3.1 summarizes the results of this mutagenesis. 
Assembly-positive mutants were defined as mutations that resulted in at least five VLPs 
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Figure 3.1: The SPA helix and its location within ΔMBDΔPR. The SPA helix 
sequence was determined from secondary structure prediction and is enumerated from 
the first residue of RSV Gag.    
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Table 3.1: Alanine scan mutants and their assembly results. All mutations were 
made within ΔMBDΔPR. Mutations that allow assembly are indicated with a “+” symbol. 
Mutations that abrogate assembly are indicated with a “-” symbol.  
Mutation  Assembly  Mutation  Assembly  
D472A  + I483A  -  
Q473A + Q484A  -  
G474A  + P485A  -  
I475A -  L486A -  
A476S  -  I487A -  
A477S  +  M488A  -  
A478S  -  A489S  -  
M479A  -  V490A  -  
S480A  +  V491A  +  
S481A  +  N492A  +  
A482S  -    
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per EM grid. Assembly of the wild type protein ΔMBDΔPR was used as a control and 
invariably resulted in many VLPs per field (Figure 3.2). The assembly-negative 
phenotype usually appeared as large regions of protein aggregation with no sign of 
VLPs (representative example shown in Figure 3.2). Some assembly-positive mutants 
could assemble at near wild-type efficiency, but more often produced fewer particles 
than ΔMBDΔPR assembly (Figure 3.2). None of the mutations resulted in other 
morphologies, for example tubular assembly. 
Residues around and including RSV SP form an amphipathic helix when plotted 
into a helical wheel [107]. We generated a helical wheel using the extended SPA helix 
sequence and found that this longer sequence also forms an amphipathic helix with a 
large hydrophobic face and a smaller hydrophilic face (Figure 3.3). With the exception of 
D472A (the first residue on the helical wheel), all the mutations that did not disrupt 
assembly (indicated by asterisks) are located on the hydrophilic face of the helix. 
Furthermore, it appears that every residue on the hydrophilic face, except Q484, can be 
mutated without compromising assembly. This finding is in agreement with the idea that 
the SPA helix contributes to immature assembly by forming an amphipathic helix that 
mediates Gag-Gag interaction through hydrophobic contacts. 
Cysteine point mutation results mostly mirror alanine mutations  
In addition to the alanine and serine mutations, I also mutated each residue in 
SPA helix to cysteine. Cysteine mutants were all made in ΔMBDΔPR(-11C), in which 11 
of the 12 native cysteines were mutated to alanine or serine, with the exception of one 
buried and presumed non-reactive cysteine in CACTD [72]. The rationale behind the 
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Figure 3.2: Examples of observed in vitro assembly using negative stain EM. 
ΔMBDΔPR (wild type protein, control). Assembly-negative mutant (A478S). Assembly-
positive mutant (M488A). Scale bars are 500 nm.   
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Figure 3.3: Helical wheel projection of SPA helix sequence. Each residue is 
enumerated according to its position within full-length RSV Gag. Polar, uncharged 
residues are green, negatively charged residues are pink, and non-polar/hydrophobic 
residues are yellow. Residues indicated by asterisks can be mutated to alanine without 
abrogating in vitro assembly. 
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cysteine mutagenesis was two-fold. First, for most residues in the SPA helix, changing 
the native amino acids to cysteine is a more disruptive structural change than changing 
them to alanine and should result in a loss of assembly. However, the more 
conservative mutations (serine, valine, and methionine to cysteine) may lead to different 
assembly outcomes when compared to alanine mutations. Second, the presence of a 
free sulfhydryl group is conducive to labeling and cross-linking experiments.  
The cysteine mutation results mostly mirror those from the alanine scan, with a 
few notable exceptions (Table 3.2). The first three residues (D472, Q473, G474) at the N-
terminus of SPA helix did not tolerate mutation to cysteine, but did tolerate mutation to 
alanine. The opposite was observed with V490. D472 is likely the helix-capping residue, 
and mutation to cysteine may have been too disruptive to its role in stabilizing the N-
terminus of the predicted helix, although it is difficult to envision why mutation to alanine 
is more readily tolerated. Although they are located on the hydrophilic face of the 
predicted helix, Q473C, and G474C are assembly-defective mutations. This is likely 
because the nature of the side-chains is dramatically changed and any side-chain 
interactions mediated by these residues outside of those found in the presumed 6HB 
may be disrupted in the assembling VLP. V490C is a more conservative mutation, which 
may explain why it is a tolerated mutation in assembly, while V490A is not.  
Insertion or substitution mutations in SPA mostly abrogate assembly 
Whether the SPA helix can be replaced by another helical segment is unknown. 
It is also unknown if the helix can be extended by a turn or two without affecting its 
function in the protein. I assumed that if the role of the SPA helix is simply a structural   
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Mutation Assembly Mutation Assembly 
D472C - I483C - 
Q473C - Q484C - 
G474C - P485C - 
I475C - L486C - 
A476C - I487C - 
A477C + M488C + 
A478C - A489C - 
M479C - V490C + 
S480C + V491C + 
S481C + N492C + 
A482C - 
  
 
Table 3.2: Cysteine point mutants and their assembly results. All mutations were 
made within ΔMBDΔPR(-11C). Mutations that allow assembly are indicated with a “+” 
symbol. Mutations that abrogate assembly are indicated with a “-” symbol. 
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one, meaning that merely the presence of an α-helix suffices to satisfy its contribution to 
the virion, then it should be replaceable with a helical segment from another protein or 
the length of the helix should be modifiable without severely compromising assembly. 
However, if the SPA helix forms homotypic higher-order structures like a 6HB or 
interactions with more distant parts of Gag, then it may need to be amino acid-specific. 
To address this question, I tested a panel of nine insertion or extension mutants for their 
ability to assemble. A description of each mutant can be found in Table 3.3.  
The insertion mutants are as follows: 3Ala, 7Ala1, 7Ala2 and 7AA. Of these 
mutations, the three alanine insertion mutants were made based on publications 
showing that alanine-based peptides are stably α-helical [152] and that alanine is helix-
stabilizing [153]. In particular, 3Ala was based on results from Keller et al., who showed 
that insertion of up to three alanine residues between residues D472 and Q473 does 
not affect Gag assembly in a baculovirus system [126]. The 7AA mutant elongates the 
SPA helix by repeating the last seven amino acids (LIMAVVN) of the predicted helix. 
The substitution mutants are: CMV1, CMV2, SP1sub, and SP1ins. CMV1 and CMV2 
substitute part or all of SPA helix with a helical segment of the cucumber mosaic virus 
(CMV) capsid. In the assembled CMV capsid, this helical segment is known to form a 
parallel 6HB, as determined by X-ray crystallography [154]. SP1sub and SP1ins, 
respectively, substitute or insert a sequence from HIV-1 SP1 with high predicted helical 
propensity into the SPA helix.  
Of these eight mutations, only three are assembly-competent: 3Ala, 7AA, and 
SP1sub. Why these three mutants assembled but others did not is unclear, but it may  
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Name Description Assembly 
3Ala Inserts three Ala residues between D472 and Q473 + 
7Ala1 Inserts seven Ala residues after predicted SPA helix - 
7Ala2 Inserts seven Ala residues between S480 and S481  - 
7AA Inserts LIMAVVN after M488 + 
CMV1 replaces entire SPA predicted helix with CMV helix - 
CMV2 replaces A478 – V491 with CMV helix - 
SP1sub replaces Q473 – A477 with KARVLAE from HIV-1 SP1 + 
SP1ins Inserts ARVLAEA from SP1 between M488 and A489 - 
 
Table 3.3: Insertion and substitution mutants in SPA helix and their assembly 
results. All mutations were made within ΔMBDΔPR. Mutations that did not disrupt 
assembly are indicated with a “+” symbol. Mutations that abrogate assembly are 
indicated with a “-” symbol. 
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be that they are the least disruptive to the helical propensity of the SPA domain. It is 
also possible that SPA helix forms part of a higher-order structure and mutations that 
knock the helix out of phase may prohibit that structure from forming. Finally, it is worth 
noting that both 3Ala and SP1sub insert residues after D472, the first residue in the 
predicted helix, and 7AA inserts residues at the end of SPA helix. Perhaps changes to 
helical structures are less deleterious when they are made at the helix ends. 
A conserved predicted helix is found downstream of the structured CACTD  
The structure of CA is highly conserved among retroviruses [56, 62]. The CANTD 
is composed of seven α-helices that fold into a globular shape and is linked to the 
CACTD via a flexible linker. CACTD consists of four α-helices, and X-ray structures have 
shown that the region downstream of the last (11th) helix is unstructured.  However, 
given that the unstructured region is highly sensitive to mutation, I wanted to determine 
if there is actually any structural conservation that was not detected by previous studies. 
To this end, I collected known Gag sequences from 16 orthoretrovirus species and 
submitted a structurally conserved portion of Gag, from the initiating proline in CA to the 
first zinc-finger in NC, to Psipred for secondary structure prediction. Interestingly, the 
program identified an additional predicted 12th helix downstream of the known 
structured CACTD in all cases.   
 Lentiviruses and alpharetroviruses have a cleaved spacer peptide between the 
CA and NC domains of Gag. In these two genera, the predicted 12th helix either covers 
the entire spacer region or spans the junction between CA and spacer. Betaretroviruses 
and deltaretroviruses have no cleaved spacer, but the predicted 12th helix also spans 
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the cleavage site between CA and NC. Gammaretroviruses also have no cleaved 
spacer, but there is a long stretch of highly charged amino acids immediately 
downstream of the structured CACTD that has been inferred to form a α-helix based on 
mutational studies [127]. Indeed, the predicted helix spans the length of the highly 
charged region and either overlaps the CA-NC cleavage site or is located just upstream 
of the cleavage site. The data suggest that there may be a conserved helix located 
downstream of the known structured CACTD that is not present in monomeric Gag, but 
that takes shape in the assembled Gag lattice. 
A model of the putative 6HB in assembled VLPs 
When RSV VLPs are studied using electron microscopy, the immature Gag 
hexamer appears to consist of six Gag molecules interacting laterally [107]. This 
arrangement is a conserved property of Gag assembly and has been confirmed for 
other retroviruses that have been studied at this level, notably MPMV and HIV-1 [8, 9, 
14, 23, 107, 117, 155, 156]. As the results from my mutations indicate that the SPA 
helix can form an amphipathic helix in immature assembly, I hypothesized that six of 
these helices organize into a parallel 6HB, as originally suggested for HIV-1 by Wright 
et al. [9], and that opposing sides of the large hydrophobic face are involved in contacts 
that tie the bundle together (Figure 3.4, opposing sides designated I and II). In this 
model, the hydrophilic face of each helix is oriented toward the outside of the helical 
bundle and therefore is not involved in inter-helix contacts, explaining its lack of 
sensitivity to mutation.  
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Figure 3.4: Conceptual model of the putative RSV SPA 6HB. The numbers “I” and 
“II” designate opposite, but putatively interacting sides of the large hydrophobic face. 
The approximate location of polar, uncharged residues on each helix is green and that 
of non-polar/hydrophobic residues is yellow. 
 
  
 68 
 
The SPA domain is highly protected against HDX in assembled VLPs 
The data from my point mutations suggest that the SPA helix may be capable of 
forming homotypic interactions with neighboring SPA helices in the context of an 
assembled RSV VLP. To further probe the structural contribution of the SPA helix in 
assembly, my collaborators in the Prevelige Lab at the University of Alabama at 
Birmingham used HDX MS to examine this segment of Gag, comparing free ΔMBDΔPR 
protein with assembled VLPs. HDX MS allows the monitoring of protein structure and 
dynamics by measuring the rates of exchange of protein backbone amide hydrogens 
with hydrogens from the solvent. By diluting protein into a deuterated buffer, these 
exchange events result in a 1 Da mass shift (H to D) for each exposed amide, which is 
readily detectable with mass spectrometry. The rate of this exchange is dependent on 
secondary, tertiary, and quaternary structure. Regions of a protein involved in more 
stable folds and interactions exchange more slowly than regions that form less stable 
structural elements. While this technique cannot provide explicit structural detail, 
comparisons of exchange patterns provide valuable insight into the dynamics, stability, 
and intermolecular interfaces of protein assemblies, especially in those cases where the 
atomic level structure of a protein is unknown.  
My collaborators compared the HDX profiles of ΔMBDΔPR in unassembled (free) 
and assembled (VLP) form, which I purified, assembled, and shipped to them on 
multiple occasions. The exchange plots illustrate several notable differences in HDX 
across the two states. Most important, comparisons of peptides from the SP domain 
showed very high protection following assembly (Figure 3.5). This level of protection is 
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Figure 3.5: HDX plots comparing free ΔMBDΔPR to assembled VLPs. A. The two 
peptic fragments corresponding to regions in RSV SP are underlined. Vertical lines 
correspond to natural protease cleavage sites in Gag. B. Mass to charge spectra for the 
shorter peptide 482 – 488 in unassembled ΔMBDΔPR protein (blue) and assembled 
VLP (red). C. Plot of deuterium incorporation in peptide 482 – 488 and D. peptide 477 – 
488 at different time-points. 
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suggestive of a very stable ultrastructural element, and thus is consistent with the 
proposed helical bundle motif [107]. Although our collaborators were not able to find a 
peptide that spanned the entire length of the SPA helix, they were able to examine two 
relevant peptides: a longer fragment spanning residues 477 - 488 (AAMSSAIQPLIM) 
and a shorter one including residues 482 – 488 (AIQPLIM). Both showed very similar 
exchange and protection patterns. This result indicates that the structural stability 
afforded by the assembled lattice is likely to entail the complete SP domain and not just 
the N- or C-terminal portion. Furthermore, the low level of protection of the same region 
observed in the unassembled protein suggests that this region may be unstructured 
before assembly, consistent with previously published structures of CA or CA fragments 
that showed an unstructured coil downstream of CACTD  helix 11 [53, 54, 57]. 
SPApep becomes more structured with increasing peptide concentration 
To investigate the mechanism underlying the structural transformation of the SPA 
helix during assembly, I performed circular dichroism (CD) spectroscopy on a 29 amino 
acid peptide (PLTDQGIAAAMSSAIQPLIMAVVNRERDC) named SPApep. It includes 
the last eight residues of CA, all of SP, the first eight residues of NC, and an extra C-
terminal ectopic cysteine for potential labeling experiments. Preliminary experiments in 
the presence and absence of 1 mM tris(2-carboxyethyl)phosphine (TCEP, a reducing 
agent) revealed no difference in the CD spectra. Therefore, I inferred that the additional 
cysteine residue does not interfere with peptide structure (data not shown).  
I measured the CD spectra of SPApep at various concentrations in aqueous 
buffer, from 0.033 mM (0.1 mg/mL) to 3.3 mM (10 mg/mL). These experiments were 
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repeated by my collaborators in the Prevelige lab, as they have the 0.1 mm path length 
Hellma quartz cuvette required to take CD measurements at high concentrations and 
far-UV wavelengths. Previously published work showed that the CD spectra of a similar 
peptide based on the HIV-1 SP1 region became more helical as peptide concentration 
was increased [102]. Due to the structural similarity between HIV-1 and RSV VLPs [106, 
107], I predicted that SPApep should exhibit similar behaviors when its concentration is 
increased. Indeed, the CD spectrum of SPApep began to shift from coil to helix at 1.6 
mM (5 mg/mL) and became significantly more helical at 3.3 mM (Figure 3.6). At 3.3 mM, 
a noticeable maximum at 197 nm and local minima at 206 nm and 222 nm appeared in 
the spectrum, with the calculated helicity of the peptide increasing to 23% (Figure 3.6). 
SPApep became more α-helical at a concentration similar to what was previously 
reported using the HIV-1 SP1 peptide [102]. My finding suggests that the SPA helix 
region becomes more structured within an assembling virus particle, because the local 
Gag concentration might reach values around 4 mM, as roughly calculated using an 
average immature viral diameter of 129 nm and 2500 Gag proteins per virion [106].  
To definitively rule out any contribution of cysteine cross-linking leading to 
unwanted nucleation, my collaborators at the Prevelige lab repeated the CD 
measurements using a version of SPApep that did not contain the exogenous cysteine 
and saw nearly identical CD spectra for the cysteine-free peptide (Figure 3.7). 
SPApep becomes more structured with increasing TFE concentration 
To further probe the concentration-dependent structural transition of SPApep, I 
analyzed the conformation of SPApep in the presence and absence of trifluoroethanol 
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Figure 3.6: CD spectra of SPApep at various concentrations. A) At lower 
concentrations (0.6 mg/mL – 2.5 mg/mL), SPApep displays CD spectra similar to an 
unstructured coil. A structural shift begins at 5 mg/mL, and by 10 mg/mL, SPApep 
begins to display two characteristic local minima at 208 nm and 222 nm, indicative of 
helical structure. B) The percent helicity of SPApep was quantified using PEPfit. 
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Figure 3.7: CD spectra of SPApep (without cysteine) in aqueous buffer. The CD 
spectra at 1 mg/mL (diamond), 5 mg/mL (square), and 10 mg/mL (circle) are very 
similar to the spectra measured using SPApep containing an exogenous cysteine. 
These experiments were performed by our collaborators in the Prevelige Lab. 
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(TFE) with various peptide concentrations. It had been shown that another peptide that 
included HIV-1 SP1 takes on an amphipathic α-helical structure in 30% TFE, as 
determined by NMR [125]. Although TFE is often used as a helix-stabilizing solvent in 
NMR and CD studies [157], it can induce non-native α-helical structures . This becomes 
particularly relevant with peptides, where nonlocal interactions that stabilize the native 
protein conformation are nonexistent [158]. I diluted SPApep into solvent containing 0% 
– 30% TFE to a final concentration of either 0.033 mM or 0.20 mM and measured the 
CD spectra. At 0.033 mM, SPApep showed significantly increased helicity in 20% TFE, 
which is lower than the concentration used to induce helix formation in the 
aforementioned HIV-1 SP1 study. At a peptide concentration of 0.20 mM, a clear coil to 
helix transition took place in 15% TFE (Figure 3.8). In summary, these results reveal 
that with SPApep, both the increase in peptide concentration and addition of TFE can 
independently induce helix formation, and that these two variables have additive effects. 
The SP assembly peptide associates into a hexamer in a concentration-
dependent manner 
My collaborators in the Prevelige lab also employed sedimentation velocity AUC 
to directly probe SPApep oligomerization in solution, using the cysteine-free version of 
SPApep. An increase in s-value with increasing concentration is expected for a species 
in rapid association/dissociation equilibrium, as higher peptide concentration favors the 
associated state. At all three concentrations measured, 1 mg/mL, 5 mg/mL, and 10 
mg/mL (0.33 mM, 1.7 mM, and 3.3 mM, respectively), the c(s) distribution displays a 
peak at approximately 0.2 s (Figure 3.9, A).   At 0.33 mM the peak is skewed, trailing  
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Figure 3.8: CD spectra of SPApep in TFE. A) The CD spectra of SPApep at 0.6 
mg/mL concentration in varying amounts of TFE. At 0.6 mg/mL (0.2 mM), SPApep 
begins to show helical characteristics when 15% TFE is added to the solution. C) The 
CD spectra of SPApep at 0.1 mg/mL concentration in varying amounts of TFE. At 0.1 
mg/mL (0.033 mM), SPApep begins to show helical characteristics when 20% TFE is 
added. B) & D) are the calculated percent helicity of SPApep in increasing TFE 
concentrations. 
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Figure 3.9: Sedimentation velocity analysis of SPApep at 10 mg/mL. A) 
Sedimentation velocity AUC shows that SPApep associates as its concentration is 
increased.  B) c(s,ffo) model fit of the 3.3 mM (10 mg/mL) species indicating that its 
molecular weight is nearly identical to that of a hexameric species of SPApep. These 
data were generated by our collaborators in the Prevelige Lab. 
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towards higher s-values and as the loading concentration is increased a second peak at 
approximately 0.2 s (Figure 3.9, A).   At 0.33 mM the peak is skewed, trailing towards 
higher s-values and as the loading concentration is increased a second peak becomes 
evident. The failure to achieve baseline separation, as well as the concentration 
dependent shift of the second peak, is a consequence of the fact that the species are in 
rapid equilibrium.  
The sedimentation rate is influenced by both the molecular weight and the shape 
of the molecule. Information about the shape (frictional coefficient) of the molecule is 
required to accurately calculate the molecular weight. Determination of the shape factor 
can be accomplished by modeling the diffusion-induced broadening of the 
experimentally measured boundary profiles.  To determine the molecular weight of the 
fastest sedimenting species, the data from the 3.3 mM sample were fit with a two-
dimensional c(s,ffo) model (Figure 3.9, B).  Consistent with the one-dimensional fit, the 
predominant species has a weight-average sedimentation coefficient of 1.65 S.  The 
weight-average molecular weight of this species was determined to be 17854 Da, very 
close to the expected mass of a 6HB derived from SPApep (17808 Da) and providing 
strong evidence that SPApep forms a 6HB in solution. 
A computer-generated model of the putative SPA 6HB 
Currently, three parallel, homotypic 6HBs have been described at atomic 
resolution. The first 6HB was discovered and solved as part of a 3.2 Å x-ray structure of 
the CMV capsid (PDB ID 1F15) [154]. The second 6HB forms the central pore of a 
hexameric tyrosine-coordinated heme protein (HTHP) from Silicibacter pomeroyi and is 
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part of a 2.5 Å x-ray structure (PDB ID 2OYY) [159]. The most recent 6HB comes from 
the assembly of a synthetic peptide named CChex, which was designed with the goal of 
engineering protein pores (PDB ID 3R3K) [160]. Each of the constituent helices in the 
CMV 6HB is made of 17 residues. In the HTHP 6HB, each helix is made of 21 residues. 
In the CChex 6HB, each helix is made of 32 residues. I used Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) to align the amino acid sequence of each of 
these helices with RSV SPA, and found CChex to be most similar in sequence. Using the 
Clustal Omega sequence homology as a guide, I modeled the cysteine-free SPApep 
onto the structure of CChex with Swiss PDB-Viewer (http://www.expasy.org/spdbv/) to 
generate an idea of what the SPApep 6HB would look like.  
The Swiss PDB Viewer model of RSV SPApep is strikingly similar to our 
predicted model of the RSV 6HB (Figure 3.4 & 3.10).  Residues that do not tolerate 
mutations are found either on the inside of the helical bundle or mediate contacts 
between helices. Mutable residues do not appear to contact neighboring helices. 
Molecular surface calculations reveal a seam of interacting surfaces that run down the 
length of each pair of helices (Figure 3.11). Each individual helix interacts with two 
adjacent helices using two opposing sides of the helix, creating the same heterotypic I/II 
interaction illustrated in Figure 3.5 around the entire 6HB (Figure 3.11). The putative 
interacting residues are listed in Table 3.4 and highlighted in red in Figure 3.11 and 
correspond closely to residues that do not tolerate point mutations. The exceptions are 
D472, Q473, and S480, which can all be mutated to alanine, and S480 which can even be 
mutated to cysteine. As previously observed, mutations at the beginning of the  
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Figure 3.10: Structural alignment model of RSV SPA 6HB. The lateral view of the 
putative 6HB is on the left, while the top-down view is on the right. 
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Figure 3.11: Hydrophobic seam between neighboring interacting helices in 6HB. 
The molecular surface of one helix is outlined in yellow mesh. The adjacent helix is 
represented in cartoon form. The interaction surface between the two helices is colored 
blue and the putative interacting residues are colored red and listed in Table 3.4. Helix 
A is represented in cartoon form on the left, and helix B is represented in cartoon form 
on the right. 
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Helix A Helix B 
D472 Q473 
I475 A476 
M479 S480 
A482 I483 
L486 I487 
A489 V490 
R493 E494 
 
Table 3.4: Putative interacting residues in neighboring helices. 
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Figure 3.12: A salt bridge between residues R493 and E494 of neighboring helices 
may stabilize the putative 6HB. The yellow line illustrates the putative salt bridge that 
may be formed. 
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predicted SPA helix may be more easily tolerated. S480, on the other hand, appears to fit 
into a wide groove in the adjacent helix formed at least in part by M479. Therefore, it 
appears that substitution with alanine or cysteine is tolerated, as they are both small 
and relatively non-polar. The Swiss PDB Viewer model also reveals a salt bridge at the 
base of the model 6HB between the side chains of R493 and E494 (Figure 3.12), two 
residues that are positioned approximately 4 Å from each other. Furthermore, charged 
residues immediately downstream of the predicted spacer helix have been implicated in 
assembly in a number of retroviruses [76, 147, 161]. Despite applying a de novo 
approach to model the putative RSV 6HB, the end result corresponds closely to the 
model generated from my point mutations and supports the hypothesis that a 6HB plays 
a critical structural role in immature assembly. 
DISCUSSION 
The data presented in this study strongly support the hypothesis that a predicted 
amphipathic helix overlaps the RSV SPA domain. I identified residues within the SPA 
helix that are critical for immature assembly and that may be involved in a putative 6HB 
that promotes immature virus formation. The existence of this helical bundle is 
supported by results of biophysical analyses demonstrating that a stable, self-
associating, hexameric element is able to take on helical conformation in a 
concentration-dependent manner in the SPA region of assembled VLPs. My results, in 
conjunction with data from our collaborators in the Prevelige lab, strongly support a 
model of the SPA domain forming a 6HB in immature assembly, but do not prove that 
the model is correct.      
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One proposed structure for the RSV SPA helix is a 6HB. Although parallel, 
homotypic 6HBs are relatively rare, one naturally-occurring 6HB exists in the CMV 
capsid [154] and another at the core of HTHP [159]. The only example of a free-
standing 6HB is from a study of synthetic helical bundles illustrating the fundamental 
concepts behind helical pore formation [160]. Similar to the three existing structures, I 
have modeled the RSV putative SPA helix bundle with hydrophobic interactions on the 
inside and along helix-helix contacts and with hydrophilic residues on the outside 
(Figure 2B, Swiss PDB Viewer model). Hydrophobic interactions are known to 
contribute critical contacts in well-defined α-helical tertiary structures such as leucine 
zippers and coiled-coils. Our mutation and modeling data suggest that if the SPA 
domain is a 6HB in immature virions, the interactions that hold the bundle together 
would form a hydrophobic seam along the length of two neighboring helices, similar to 
previously described 6HBs.  
Interestingly, charged residues downstream of the predicted SPA helix also play 
a role in assembly. Keller et al. mapped the SPA domain to include the first four 
residues of NC and excluded the four charged residues that followed [126]. However, 
there are indications that at least a couple of these four residues play a structural role in 
assembly. The two arginine residues were previously shown to be critical for assembly 
of a truncated, purified version of ΔMBDΔPR, since they did not tolerate mutation to 
alanine  [76]. A similar requirement for at least two basic residues downstream of an 
SP-like domain was identified in MPMV [147], while in HIV-1, two arginine residues near 
the N-terminus of the NC domain) are required for proper VLP formation [161]. I 
included these four residues in SPApep to enhance peptide solubility, as I hypothesize 
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that they play a role in stabilizing the higher-order structure of the peptide hexamer. In 
fact, my Swiss PDB Viewer model of the putative RSV 6HB places R493 and E494 at the 
seam between two SPApep helices, suggesting that these two residues form an inter-
helix salt bridge. 
What might a 6HB be doing under the organized CA lattice? One hypothesis is 
that the 6HB is a transient structure that helps stabilize the upstream CA domain into its 
immature conformation. However, no helix has ever been observed in the region 
downstream of CACTD, and my data as well as data presented by Datta et al. suggest 
that helical structure in that region only forms in a concentration-dependent or 
chemically-induced manner [102]. The metastable nature of this region may be the key 
to the function of SPA in RSV assembly and maturation. I speculate that during the 
early steps of assembly, Gag converges to the PM, increasing the local concentration 
and allowing SPA to shift from unstructured to helical. The CA domain is highly flexible 
due to the floppy CANTD-CACTD linker and may sample many possible conformations 
during initial dimerization and multimerization. Formation of the 6HB may force the 
CACTD to expose surfaces favorable for immature assembly, and these downstream 
spatial constraints could propagate upstream into CANTD. The CANTD hexamer is then 
locked in place by its interactions with the upstream p10 residues, securely fastening 
both ends of the Gag hexamer. The 6HB itself likely also has considerable flexibility, 
which may explain why even at peptide levels approaching virion Gag levels, the time-
averaged percent helicity of the SPApep does not exceed 23%. This may reflect 
significant “breathing” of the helix to allow protease to release CA during maturation. 
The relatively high level of order at the CA-SP junction may also explain why in both 
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RSV and HIV-1, cleavage of SP and SP1 from CA are the last steps in maturation [162, 
163]. 
Can one 6HB functionally replace another? Although the answer is ambiguous, it 
is heavily weighted towards no. The first experiments that attempted to address this 
question used an assembly-competent chimeric BIV Gag in which domains downstream 
of the p3 spacer were replaced with their cognate HIV-1 Gag domains. When p3 was 
substituted with SP1, virus production was abolished. However, p3 can be replaced by 
short, five residue-long sequences derived from the spacer domains from feline 
immunodeficiency virus, EIAV, and an N-terminal NC fragment from Visna virus without 
severely compromising virus production and reverse transcriptase activity [164]. A 
similar set of experiments using RSV Gag showed that sequences downstream of the 
structured CACTD cannot be replaced by homologous sequences from HIV-1 without 
compromising VLP assembly [126], but when I exchanged five amino acids at the 
beginning of the SPA helix with seven residues downstream of the structured HIV-1 CA 
having the highest predicted helical propensity (SP1sub mutant), the protein assembled 
in vitro. In MPMV, when the SP-like region at the N-terminus of NC is replaced by HIV-1 
SP1, no virus assembly is observed [147].  
The amino acid specificity of the spacer region across retroviral genera suggests 
that there may be contacts beside the putative homotypic inter-helix interactions that 
exist between SP and other Gag domains. In fact, using the maturation inhibitor PF-
46396, Waki et al. mapped a novel binding pocket formed by the major homology region 
(MHR) of HIV-1 CA and SP1 and predicted that these two distant regions may be in 
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close proximity in an assembled virus [30]. This inference is supported by data from 
Bowzard et al. that showed the rescue of a lethal MHR mutation in RSV CA by a 
second-site suppressor mutation in SP [70]. Given the apparent conservation of a SP-
like domain and the absolute conservation of the MHR across all retroviral genera, 
perhaps this putative interaction surface between SP and the MHR should be further 
investigated for its role in stabilizing the immature retrovirus.   
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CHAPTER FOUR 
CRYSTALLOGRAPHY OF A MINIMAL GAG PROTEIN AND THE SPA PEPTIDE 
INTRODUCTION 
Short sequences or structural motifs that flank the CA domain of Gag have come 
to be known as molecular switches. They are thus named because in their absence, a 
morphological transformation from immature assembly to mature-like assembly is 
triggered. Upstream and downstream switches have been characterized for RSV, HIV-
1, and to a lesser extent, MPMV and MLV. In HIV-1 and MPMV, the upstream switch 
appears to be an N-terminal extension of the CA domain, or a mutation of the N-
terminal proline of the mature CA, either of which prevents formation of the conserved 
proline-aspartic acid salt bridge in CA [131, 134]. In MLV, deletion of p12, the late 
domain-containing minor cleavage product between the MA and CA domains, results in 
mature-like tubular assembly [95]. Substitution of p12 with RSV p2 or HIV-1 p6, both of 
which are also late domain-containing minor domains, partially rescues the immature 
assembly phenotype [96]. This result suggests that MLV may require specific late 
domain-associated sequences to form immature VLPs, and that a hindrance to the 
formation of the N-terminal salt bridge is insufficient. In RSV, the last 25 residues of the 
p10 domain, which is located immediately upstream of the CA domain, are essential for 
immature assembly. Molecular modeling and thiol cross-linking experiments performed 
in our lab showed that several of these residues form an inter-molecular interface 
unique to the immature hexamer that serves to lock the CANTD in its immature 
conformation [72]. 
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The downstream switches in RSV and HIV-1 are the cleaved SP and SP1 
domains, respectively, which have been proposed to form a six-helix bundle (6HB) that 
ties together the immature hexamer [9]. Secondary structure predictions assign a helical 
structure to both the SP and SP1 domains, and cryo-EM has shown a structured density 
downstream of the ordered CACTD in immature VLPs [9, 107]. This feature may be 
conserved in MLV as well, as MLV CA has a highly charged region at the C-terminus of 
the CACTD that is predicted to form an α-helix. This predicted helix may contribute to a 
higher-order structure such as a 6HB, as deletion mutations in this region do not affect 
immature assembly as long as they remove complete turns of the helix [127]. In MPMV, 
a 15 residue stretch at the N-terminus of NC has also been found to be crucial for 
immature assembly [147], and my data from Chapter 3 suggest that these residues form 
part of a predicted 12th helix spanning the junction between the CA and NC domains. 
The immature Gag hexamer has been examined extensively using cryo-EM 
tomography and sub-tomogram averaging. Both HIV-1 and RSV have been studied 
using these techniques and the most complete report on the immature core lattice is an 
8 Å structure of MPMV VLPs obtained using a combination of cryo-EM tomography and 
fitting in high-resolution crystal structures of CANTD and CACTD [8, 9, 107, 117]. Although 
these studies have provided much insight on the differences in organization between 
the immature and mature lattices, there is no high-resolution structure of the immature 
lattice complete with both the upstream and downstream molecular switches.  
Currently, there is no evidence to suggest that a common structural element in all 
retroviral Gag proteins underlies the upstream switch in immature retroviral assembly, 
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but the downstream switch appears to be conserved, at least in RSV and HIV-1. The 
structural contribution that the spacer region makes to immature assembly is unclear for 
two reasons. First, there is no structure of the spacer region in the available crystal 
structures of CA and downstream domains [54, 56, 57, 65]. Second, in the absence of a 
crystal structure, it is impossible to assign visible densities in the immature lattice, such 
as those observed in HIV-1 and RSV [107], to any specific part of Gag. Although the 
SPA 6HB hypothesis is strongly supported by the data presented in Chapter 3 of this 
dissertation, a crystal structure of the putative 6HB would provide conclusive evidence. 
In this chapter, I will describe my efforts to obtain atomic level structural 
information on the immature RSV Gag lattice and the putative SPA domain 6HB. To do 
this, I have designed, expressed, and crystallized two minimal versions of Gag known 
as 25CASP and 25CASP(CC), as well as N- and C-terminal deletion mutants of 
25CASP. I have tried to template crystal formation by linking 25CASP to the 
hexamerizing protein Ccmk2, and by linking the hexamer template HTHP to the SPA 
sequence. Finally, I performed a crystallization trial on the SPA peptide described in the 
previous chapter and found several crystallization conditions. So far, SPApep has 
shown the most promise in delivering a structure that may help us to understand the 
role that the spacer region plays in immature retroviral assembly. 
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RESULTS 
A minimal Gag protein (25CASP) can be purified using nickel-affinity and size-
exclusion chromatography 
Multi-domain proteins are often difficult to crystallize, as their inherent flexibility 
often prevents them from packing regularly. To reduce flexibility in Gag, I made a 
“minimal” RSV Gag construct that contains solely the domains that we know to be 
essential for immature assembly: the last 25 amino acids of p10, all of CA, and the SPA 
domain (Figure 4.1). This “minimal Gag” construct was named 25CASP. A version of 
this protein was also made using a previously characterized version of ΔMBDΔPR(-
11C)  with two exogenous cysteines in p10 and CANTD that cross-link the immature 
CANTD hexamer [72]. This protein was named 25CASP(CC). The rationale is that these 
two cysteines may help stabilize any hexamers that form during crystallization. Both 
25CASP and 25CASP(CC) have theoretical molecular weights of approximately 30 kD, 
but their migration through SDS-polyacrylamide gels closely mimic that of the 25 kD 
molecular weight marker. 
As 25CASP was a novel protein that had never been expressed in E. coli, I attached a 
small ubiquitin-like modifier (SUMO) tag to its N-terminus to facilitate the purification. 
The SUMO vector was developed to enhance protein expression and solubility in E. 
coli, and a highly specific protease, Ulp1, cuts the tag efficiently to liberate the desired 
protein product. Additionally, in this system both SUMO and Ulp1 are tagged with a 
poly-histidine tag. In essence, a SUMO-tagged protein is purified using two-step nickel-
affinity purification. In the first step, the SUMO-tagged protein is bound to the nickel- 
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Figure 4.1: Schematic diagrams of Gag-derived constructs used for X-ray 
crystallography. Full-length RSV Gag is designated FL Gag. 25CASP contains the 
parts of Gag deemed to be essential for immature assembly. SUMO-25CASP is 
25CASP fused to a SUMO tag, while SUMO-25CASP(CC) contains two exogenous 
cysteines, locations indicated by the two red asterisks. SUMO-Ccmk2-25CASP is the 
hexamer-templated construct. 
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affinity column and separated from other E. coli proteins; in the second step, SUMO is 
proteolytically cleaved from the protein of interest, and SUMO and Ulp1 are bound to 
the nickel-affinity column, while the protein of interest flows through (Invitrogen SUMO 
protease manual, Cat. No. 12588-018). SUMO-25CASP is predicted to be a 44 kD 
protein, but migrates through poly-acrylamide gels only slightly above the 37 kD marker. 
Figure 4.2 shows a typical purification process for 25CASP. SUMO-25CASP was 
highly expressed and efficiently cleaved by Ulp1 in an overnight dialysis into imidazole-
free buffer. The cleaved 25CASP remained highly soluble in a high salt buffer (20 mM 
sodium phosphate dibasic, pH 8.0, 500 mM NaCl, 10 mM imidazole) and could be 
purified to approximately 95% purity after a second pass over a nickel-affinity column. 
25CASP remained soluble when dialyzed into a low salt buffer (20 mM Tris, pH 8.0, 100 
mM NaCl) for gel filtration and eluted from a size-exclusion column as a single peak 
with a small shoulder. Fractions corresponding to the peak were collected and assayed 
for purity by SDS-PAGE. The fractions with the highest ratio of 25CASP to 
contaminants were pooled and concentrated to >5 mg/mL in the low salt buffer for 
crystallography trials (Figure 4.3). 
25CASP forms micro-crystals upon initial screening and can be improved to 
needle clusters in a hanging drop 
My initial crystallization screen used a total of 480 conditions in sitting drops, 
dispensed using an ARI Phoenix liquid handling system. Of these conditions, only one 
was found to foster crystal growth for 25CASP (0.1 M sodium citrate, pH 5.5, 0.2 M 
lithium sulfate, 15% ethanol), and a different condition led to crystal growth for  
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Figure 4.2: Purification of 25CASP using a SUMO-tagged protein. On the left, the 
full-length SUMO fusion protein is eluted off the nickel-affinity column (left, boxed in 
red). After dialysis with Ulp1 protease, the SUMO protein is cleaved off and both SUMO 
and Ulp1 are bound to a second nickel-affinity column. The flow-through of the second 
nickel-affinity column is the protein of interest, in this case, 25CASP (right, boxed in 
red). 
  
 95 
 
 
Figure 4.3: Gel filtration and SDS-PAGE of 25CASP. 25CASP mostly elutes off the 
size-exclusion column as a single peak after approximately 80 mL (left). The injected 
protein has several higher molecular weight contaminants or oligomers (lane 1), but 
these are removed from the eluted fractions (lanes 2 – 7). Lane L is the molecular 
weight ladder. 
  
1      L    2    3     4      5     6      7 
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25CASP(CC) (0.1 M sodium/potassium phosphate, pH 6.2, 10% PEG-3350). For both 
proteins, the crystals formed were tiny two-dimensional micro-crystals approximately 
one micron in length. Both conditions were optimized by varying the pH, as well as the 
protein, salt, and precipitant conditions found in the initial hit, as well as scaling up the 
drop size in a hanging drop. Simply by altering the conditions of the initial hit, 25CASP 
was optimized to needle clusters approximately 1 mm in diameter, but further 
optimization using different precipitants did not enhance crystal growth (Figure 4.4). 
Unfortunately, these needle clusters were too small for diffraction. The initial hit for 
25CASP(CC) contained a phosphate buffer known to produce salt crystals. I changed 
the buffer to 2-(N-morpholino)ethanesulfonic acid (MES) buffer for the optimization and 
observed no crystal formation, suggesting that the microcrystals seen in the initial hit 
may have been salt crystals. 
N-terminal and C-terminal deletions of 25CASP greatly affect protein solubility 
When proteins fail to crystallize during optimization, the logical next step is to 
optimize the protein construct itself. A common method to optimize constructs is by 
truncating the protein by a few amino acids at the N- or C-terminus. However, as 
25CASP only includes the domains of Gag that are necessary for assembly, the number 
of possible N-terminal and C-terminal mutations is limited.  
To generate proteins that may be more amenable to crystallization, I generated 
the following three mutants: ΔN3, ΔC2, ΔN3C2. ΔN3 removes the first three amino 
acids in 25CASP (P215, G216, P217), ΔC2 removes the last two (V491, N492), and ΔN3C2 
removes all five aforementioned residues. I proceeded with the two-step nickel-affinity  
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Figure 4.4: Optimization of 25CASP. A single hit in the initial screen produced tiny 
crystals (left). After optimizing the buffer pH (0.1 M sodium citrate, pH 5.0 – 6.5), salt 
concentration (lithium sulfate, 0 M – 0.3 M), and concentration of precipitant (ethanol, 5 
– 15%), the crystals grew into larger needle clusters (right).  
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Figure 4.5: SUMO-25CASPΔN3C2 cannot be cleaved by Ulp1. The contents of the 
lanes are as follows: 1) nickel-affinity column flow-through; 2) column wash; 3) elution; 
4) dialysis with Ulp1; 5) second nickel-affinity column flow-through; 6) column elution; L, 
molecular weight ladder. A proportionate amount of each fraction was run on each lane. 
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purification described in the first section of this chapter, and all three mutant proteins 
are well-expressed in E. coli as a SUMO fusion and can be easily purified. However, 
when I dialyzed and cleaved the SUMO fusion proteins with Ulp1, the SUMO tag was 
not removed (Figure 4.5). This unlikely result was repeated several times with all three 
constructs, and only the ΔC2 construct was able to be cleaved by Ulp1. Since Ulp1 
recognizes a structural element in SUMO rather than a primary amino acid sequence, it 
is my belief that ΔN3 and ΔN3C2 mis-fold and conceal the Ulp1 cleavage site in SUMO. 
I continued to work with ΔC2, but encountered additional expression and purification 
problems, which eventually led me to abandon the construct optimization portion of this 
project.  
A hexamer-templated minimal Gag protein aggregates and precipitates during 
purification 
Previous work by Pornillos et al. has shown that templated crystal formation is a 
viable way of generating retroviral CA crystals [64]. Knowing that Gag assembles into a 
hexamer in VLPs, I used a protein with known hexamer structure to induce hexamer 
formation in 25CASP. Ccmk2 is a carboxysome shell protein from a cyanobacterium 
[137]. The crystal structure of the protein hexamer is shown in Figure 4.6. The C-termini 
of the Ccmk2 hexamer are approximately 5 – 7 Å apart. I reasoned that these distances 
should be close enough to bring six units of Gag together, but they may be too close 
and impose unnecessary constraints on Gag folding and inter-molecular interactions. 
Therefore, I placed three alanines between the template and 25CASP to introduce 
some flexibility. The final construct was named SUMO-Ccmk2-25CASP and has a   
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Figure 4.6: Crystal structure of Ccmk2 hexamer. The C-terminal end of each 
monomer points toward the inside of the pore formed by the hexamer. In each view of 
the structure, the C-terminal end of one monomer is boxed in red. 
  
 101 
 
predicted molecular weight of 46 kD, but the observed size on poly-acrylamide gels is 
closer to 50 kD.SUMO-Ccmk2-25CASP proved quite difficult to purify. The protein was 
not highly expressed in E. coli and it often precipitated out of solution during the 
purification process, most often when the concentration of sodium chloride was reduced 
or when SUMO was cleaved (Figure 4.7, lane 7 is the precipitated fraction). Given that 
Ccmk2 forms part of the bacterial carboxysome, a highly organized protein structure in 
many ways similar to a viral capsid, it is likely that the Ccmk2 domain tries to assemble, 
leading to protein precipitation. By maintaining a 1 M concentration of sodium chloride in 
all buffers, I was able to purify Ccmk2-25CASP successfully. Presumably, the high salt 
concentration helped to disrupt electrostatic interactions between monomers that may 
mediate carboxysome assembly. Figure 4.7 shows an example of a successful Cckm2-
25CASP purification. Ccmk2-25CASP is approximately 42 kD in molecular weight, but 
migrates through poly-acrylamide gels like the 37 kD marker. 
Figure 4.8 shows the elution profile of Ccmk2-25CASP from a size-exclusion 
column. The high peak in the void volume indicates that there is considerable protein 
aggregation as the protein proceeds through the column. However, most of the protein 
seems to have remained in the second peak, as evidenced by the SDS-PAGE gel. 
Fractions from the second peak were pooled, concentrated, and subjected to an initial 
crystal screen. I found several conditions that produced plate-shaped two dimensional 
crystals. The condition that produced the best crystals was 0.1 M sodium/potassium 
phosphate, pH 6.2, 0.2 M sodium chloride, 20% PEG-1000. These conditions were 
reproduced and expanded using MES buffer and plate-shaped crystals grew in a 
hanging drop. Figure 4.9 shows the morphology of these crystals.   
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Figure 4.7: Nickel-affinity purification of SUMO-Ccmk2-25CASP. The contents of 
each lane are as follows: 1) E. coli lysate; 2) nickel-affinity column flow-through; 3) 
column wash; 4) eluted SUMO-Ccmk2-25CASP; 5) dialysis with Ulp1; 6) supernatant 
fraction; 7) precipitated fraction; 8) second nickel-affinity column flow-through; 9) column 
wash; 10) elution; 11) bead fraction; L, molecular weight ladder. A proportionate amount 
of each fraction was run on each lane. The red box indicates the purified Ccmk2-
25CASP protein that was later run on a size-exclusion column. 
 
 
 
 
 
 
 
 
 
 
 103 
 
 
Gel filtration readout       SDS-PAGE of collected fractions 
 
Figure 4.8: Gel filtration and SDS-PAGE of Ccmk2-25CASP. Ccmk2-25CASP mostly 
elutes as a single broad peak. There is substantial aggregation on the column, as 
evidenced by the left-most peak (left). When the fractions are collected and assayed by 
SDS-PAGE, most of the protein is found in lanes 7 – 12 (right), which correspond to the 
broad, lower peak.  
1    L   2    3   4    5    6   7   8    9   10  11  12  13  
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Figure 4.9: Plate crystals are actually cleaved Ccmk2. The observed crystals formed 
after the purified Ccmk2-25CASP (right, second lane) was placed into a hanging drop. 
When the crystals were run on SDS-PAGE, their molecular weight corresponded to 
breakdown products of Ccmk2 (right, red box). 
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The Ccmk2-25CASP fusion protein crystals appear very similar to the description 
of Ccmk2 crystals described by Kerfeld et al. [137]. Furthermore, when the size-
exclusion column-purified Ccmk2-25CASP was concentrated and assessed for purity 
with SDS-PAGE, approximately half of the full-length protein seemed to have been 
degraded into 25 kD and 12 kD products, corresponding roughly to the size of 25CASP 
and Ccmk2, respectively. To verify that the crystals are actually composed of the entire 
fusion protein and not just a proteolytically cleaved fragment, I picked several crystals 
and evaluated them using SDS-PAGE (Figure 4.9). No band was observed at 37 kD, 25 
kD or 12 kD, but a very faint band corresponding to a product of approximately 11 kD 
was visible (Figure 4.9, red box). This unexpected result suggests that the plate-shaped 
crystals are breakdown products of Ccmk2, rather than 25CASP, and that there may 
have been protease contamination in the purified sample.   
A hexamer-templated SPA protein purifies as a doublet at low concentration 
As previous attempts to crystallize the entire immature hexamer have been 
largely unsuccessful, I turned my focus to the elusive role of SP in the hexamer. As my 
point mutation data suggested that the SPA domain forms a 6HB in immature assembly, 
I built a construct that may help template 6HB formation. The template protein is the 
hexameric tyrosine-coordinated heme protein HTHP, which has a parallel, homotypic 
6HB at its core (Figure 4.10). I added a flexible linker sequence (SSSSG) between 
HTHP and the SPA domain sequence, including the four charged amino acid residues 
putatively involved in forming an inter-helix salt bridge downstream of SPA. I named the 
construct HTHP-S4G-SPA, and its predicted molecular weight was approximately 13  
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Figure 4.10: Crystal structure of HTHP hexamer. At the center of the hexamer is the 
parallel 6HB, depicted in orange and green (left). The N- and C-termini of each 
monomer are indicated by the letters N and C, respectively (right). 
  
 107 
 
 
Figure 4.11: HTHP-S4G-SPA is purified at low concentration, despite high 
expression in E. coli. The contents of each lane are as follows: 1) E. coli lysate 
containing SUMO-HTHP-S4G-SPA; 2) nickel-affinity column flow-through; 3) column 
wash; 4) elution; 5) dialysis with Ulp1; 6) second nickel-affinity column flow-through; 7) 
column wash; 8) elution; 9) collected beads; 10) Precision Plus ladder. The purified 
HTHP-S4G-SPA is boxed in red. 
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kD. SUMO was linked to the N-terminus of this construct to facilitate purification. 
SUMO-HTHP-S4G-SPA expressed abundantly in E. coli (Figure 4.11). However, 
after cleavage of SUMO, the amount of HTHP-S4G-SPA recovered was very low. 
Nonetheless, I further purified the protein on a gel exclusion column, where it eluted in 
three distinct peaks. The leftmost peak is almost certainly aggregated protein, while the 
central peak is likely an oligomerized form. The peak to the right is probably the 
monomer. The eluted fractions corresponding to the central and right-most peaks are 
shown in lanes 5 – 10 in Figure 4.12. Although the protein injected onto the size-
exclusion column appears to be pure, HTHP-S4G-SPA elutes as a doublet, suggesting 
that there is substantial breakdown of the protein during purification. Combined with the 
low levels of protein purified, I chose to not pursue this construct.  
SPApep crystallizes as disc and plate crystals 
Our collaboration with the Prevelige Lab generated AUC data indicating that 
SPApep assembles into a higher-order structure at high concentrations, which suggests 
that SPApep may not be unstructured in solution as was previously believed. Using 
purified peptide remaining from previous CD experiments, I attempted a crystal screen 
using SPApep. Unlike 25CASP, SPApep crystallized rapidly (immediately after mixing in 
some conditions) under a multitude of conditions into mostly disc-shaped crystals. I 
found 11 conditions with the largest crystals and least amount of precipitation, and 
compared the crystallization conditions for common elements.  
Table 4.1 shows the list of conditions under which SPApep initially crystallized. 
Nearly all of the best conditions contained some percentage (8% - 25%) of polyethylene  
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Figure 4.12: HTHP-S4G-SPA purifies as a doublet at low concentration. The elution 
profile indicates that HTHP-S4G-SPA is a polydisperse protein (left). This is confirmed 
by SDS-PAGE, where the eluted fractions of HTHP-S4G-SPA run as doublets. 
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Screen name Well Condition 
Wizard I + II A6 0.1 M sodium citrate, pH 5.5, 20% PEG-3000 
Hampton Index E9 
0.05 M bis-tris, pH 6.5, 30% pentaerythritol 
ethoxylate, 0.05 M ammonium sulfate 
Hampton Index G6 
0.1 M bis-tris, pH 5.5, 25% PEG-3350, 0.2 M 
ammonium acetate 
Hampton HR2-110/2-112 D1 0.1 M sodium acetate, pH 4.6, 8% PEG-4000 
JCSG-Plus B2 20% PEG-3350, 0.2 M sodium thiocyanate 
JCSG-Plus B9 0.1 M sodium citrate, pH 5.0, 20% PEG-6000 
JCSG-Plus G8 20% PEG-3350, 0.15 M DL-malic acid 
PACT Premier B9 
0.1 M MES, pH 6.0, 20% PEG-6000, 0.2 M lithium 
chloride 
PACT Premier D4 0.1 M MMT buffer, pH 7.0, 25% PEG-1500 
PACT Premier E4 20% PEG-3350, 0.2 M potassium thiocyanate 
PACT Premier E9 20% PEG-3350, 0.2 M potassium/sodium tartrate 
 
Table 4.1: Initial screen hits for SPApep crystals. 
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glycol (PEG), ranging in molecular weight from PEG-1500 to PEG-6000, though PEG-
3350 was most common. The buffered conditions were all at or below pH 7.0, and most 
of the hits contained 0.05 M – 0.2 M of some salt. Based on the list of hits, I set up 
optimization plates that tested pH values ranging from 4.5 – 6.5 using sodium citrate 
and MES buffer, 0 – 27% PEG-3350, and 0 – 0.3 M lithium chloride. Figure 4.13 shows 
SPApep crystals obtained from a first round of optimization that appear disk-shaped or 
cylindrical, consistent with the most commonly observed morphologies in the initial 
screen. However, disc-shaped crystals without a visible flat edge may reflect irregular 
crystal packing (Yuxin Mao, personal communication). Indeed, the disc-shaped crystals 
did not diffract to sufficiently high resolution.  
I re-examined my initial screening trays and discovered six conditions under which I 
found crystals with morphologies other than the original disc shape. The two conditions 
with the best looking crystals were very similar: 0.1 M sodium acetate trihydrate, pH 4.6, 
0.2 M ammonium acetate, 20% PEG-4000 and 0.1 M sodium acetate trihydrate,pH 4.5, 
25% PEG-3350. More importantly, the crystals were shaped like flat plates and had 
distinct edges (Figure 4.13). As the two conditions found in the initial screen had the 
same buffer at virtually the same pH, I varied only the concentration of PEG-3350 and 
ammonium acetate in my optimization. Larger crystals of similar plate-like morphology 
were observed in the hanging drops. These were taken to the Cornell High Energy 
Synchrotron Source (CHESS) for x-ray diffraction on three separate occasions. 
Unfortunately, the plate crystals produced low quality diffraction patterns unsuitable for 
structure determination (Figure 4.14). This is likely due to irregular packing of the 
individual unit cells within the plate crystals. Therefore, the logical next step is to return  
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Figure 4.13: SPApep crystals take on three different morphologies. Disc-shaped 
crystals were the first observed crystal form in MES buffer (left). In some drops, longer 
rod-shaped crystals were observed together with disc crystals (center). Using sodium 
acetate buffer, plate crystals eventually formed (right).  
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Figure 4.14: Preliminary diffraction pattern of plate-shaped SPApep crystals. The 
overall diffraction pattern is on the left, and a magnified pattern is shown on the right.  
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to the initial screen and select conditions for optimization that enable crystals of a 
different morphology to form. 
DISCUSSION 
 One of the most important challenges in the field of retrovirology is to generate a 
high-resolution structure of the immature viral core, as it would allow a more complete 
understanding of the mechanism behind PR-driven maturation, as well as provide 
structural targets for potential maturation inhibitors. The recent 8 Å structure of MPMV 
VLPs obtained using cryo-EM tomography, sub-tomogram averaging and atomic-level 
structure fitting has proven to be highly informative, showing that an immature Gag-like 
protein assembles into a hexamer using completely novel interfaces when compared to 
the mature CA hexamer [117]. In this paper, specific residues involved in immature 
hexamer contacts were inferred based on the best fit of existing crystal structures, but 
the resolution of the reconstructed structure is insufficient for the conclusive assignment 
of interacting residues. Therefore, there is still a pressing need for a high-resolution 
structure of the immature core lattice. 
 So far, there has been no published crystal structure of a Gag-derived protein 
that contains the entire CA domain and both the upstream and downstream molecular 
switches for assembly. This is likely due to the inherent flexibility of the two-domain CA 
in combination with the molecular switches which may only acquire structure at the high 
concentrations favorable for assembly, at least in the case of RSV SP. With the data 
presented in this chapter, I have shown that a minimally flexible construct that contains 
the RSV CA domain and both molecular switches, termed 25CASP, can be purified to 
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high concentration and crystallized. Though the small crystals I obtained were not 
useable for X-ray crystallography, they prove that a Gag-derived protein containing all of 
the elements required for immature assembly is amenable to crystallization.  
 An alternative approach to the initial sparse matrix screening for crystal formation 
would be to assay various conditions for hexamer formation using the 25CASP(CC) 
double cysteine mutant. Using known conditions for both Gag and CA assembly, I could 
adjust salt concentrations and pH to generate conditions where hexamers can be 
observed using non-reducing SDS-PAGE as readout. This method is relatively quick, as 
over a dozen conditions can be assayed at once. Once an optimal condition for 
hexamer formation has been found, I would run the protein onto a gel filtration column 
to purify the hexameric fraction and subject that population of proteins to sparse matrix 
screening. The two cysteine mutations, located in p10 and CANTD, were characterized 
by Phillips et al. to be hexamer-linking cysteines [72]. In principle, the resulting disulfide 
cross-linking would stabilize the hexamer and minimize flexibility. 
 Conceptually, using a hexamer template to stabilize the immature retroviral Gag 
hexamer should help reduce flexibility and promote crystallization. In fact, Pornillos et al. 
showed that this approach is viable to crystallize CA [64]. The main problem I 
encountered with the hexamer-templated Ccmk2-25CASP was proteolytic cleavage in 
the linker region. To solve this issue, the proteins must be purified and kept in protease 
inhibitor at all times. Another problem was in purifying the protein, as the templated 
minimal Gag often aggregated on the gel filtration column and eluted in the void volume 
(Figure 4.8). One possible remedy for this is to vary the length of the linker and assay 
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the solubility of the resulting proteins using gel filtration (Owen Pornillos, personal 
communication). 
 Crystallization of SPApep was another big step toward solving the structure of 
the RSV downstream molecular switch. I have shown that SPApep can crystallize under 
a number of conditions and that the resulting crystals are diffraction-capable. What 
remains to be done here is to continue optimizing crystal growth, focusing specifically 
on the plate-shaped crystals, which have shown superior diffraction patterns compared 
to the rod-shaped or disc-shaped crystals. The main difficulty is in growing a sufficiently 
large crystal that is also a single crystal, as many conditions appear to favor nucleation 
rather than growth, resulting in an abundance of small crystals that are insufficient for X-
ray diffraction. Several methods exist to slow down the growth of crystals in a hanging 
drop, including lowering the protein concentration in the drop (did not work) and slowing 
down the exchange between the drop and the well solution by covering the well solution 
with silicon oil (did not try). 
 Overall, I have shown that crystallography is a viable method to produce a high-
resolution structure of the immature core lattice. With more time and further 
optimization, diffraction quality crystals can be produced for both the immature lattice 
and the putative SP 6HB.  
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CHAPTER FIVE  
PERSPECTIVES 
Studying retroviral assembly using in vitro assembly 
Currently, the best-studied immature retroviral assembly systems are those using 
some variation of the Gag protein from HIV-1, RSV, and MPMV. Purified Gag-derived 
proteins from these three retroviruses can assemble in vitro into morphologically similar 
spherical particles with an electron-lucent center [13, 76, 80, 104, 132, 136, 143, 146, 
147, 150, 151], though MPMV Gag can be coaxed into tubes bearing an immature 
lattice [117]. CA-derived proteins assemble into various morphologies that may be 
reflective of authentic mature capsids in RSV and HIV-1 capsid assemblies, but not in 
MPMV [134]. In vitro assembly has proven to be a very useful tool for the study of 
retroviral core structures, as amino acids critical for core formation can be easily 
identified through site-directed mutagenesis followed by in vitro assembly as the 
readout. In vitro assembly can also be a useful method for mapping protein-protein 
interactions, similar to higher-resolution structure analysis techniques such as X-ray 
crystallography, but has the added advantage of generating data that are almost certain 
to be biologically relevant. In vitro assembly can also generate VLPs free of cellular 
debris or contamination from unassembled protein or mis-folded aggregates, and these 
VLPs can be further analyzed on the atomic level using cryo-EM, HDX MS, or similar 
structural analyses that require high sample purity.  
The development of retroviral in vitro assembly systems has led to the discovery 
of the assembly requirements of the immature core and mature capsid. The ability of 
 118 
 
Gag and CA to self-assemble, the role of RNA in initiating assembly, the overall core 
lattice architecture, as well as the structural determinants for the switch between 
immature and mature assemblies were all discovered using in vitro assembly. The 
technique of in vitro assembly continues to prove useful for studying retroviral assembly, 
as evidenced by the data presented in this dissertation.  
Molecular switches for assembly 
The morphological similarity between immature VLPs is likely due to the 
structural homology between CANTD and CACTD in all retroviral CA proteins described so 
far [56]. However, specific contacts that promote immature assembly differ between 
retroviral species and can be found in the regions immediately adjacent to the CA 
domain. These have come to be known as conformational switches or molecular 
switches for immature assembly [72, 102, 150], since their presence seems to constrain 
the CA domain into its immature conformation. For some retroviruses, the upstream 
switch requires nothing more than residues upstream of the CA domain that prevent the 
formation of a critical salt bridge between the first proline and a conserved aspartic acid 
residue of the processed CA protein [52, 57]. Disruption to this beta-hairpin through an 
N-terminal extension results in the assembly of immature-like VLPs [131, 134]. The 
downstream switch seems to be amino acid specific, possibly due to its role in forming a 
higher-order structure, as mutations generally lead to disruption of immature assembly 
[102, 123, 124, 126, 127, 147, 150]. Although HIV-1 does not have a well-characterized 
upstream switch, a Gag-derived protein encompassing only CA through NC (CA-NC) 
assembles into tubes and cones in vitro [15, 111, 130]. RSV CA-NC also assembles 
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into tubes in vitro [15]. Tubes are generally believed to be reflective of mature assembly, 
as free CA assembles into tubes [71, 129-131, 165]. Similarly, when the downstream 
switch is deleted or disrupted, HIV-1 and RSV Gag-derived proteins may assemble into 
tubes and cones [102, 123, 124, 126, 150]. Therefore, having a single upstream or 
downstream switch is not sufficient to elicit immature assembly. 
Perhaps the best-described molecular switches governing mature and immature 
assembly are found in RSV. The upstream switch consists of 25 amino acids 
immediately upstream of CA in p10. When p10 is deleted, the mutant Gag assembles in 
vitro into tubes [13, 146]. The switch region was narrowed down to the last 25 amino 
acids in p10 using a series of truncations [146]. In the crystal structure of an N-
terminally extended CANTD dimer, six amino acids in p10 make side-chain contacts with 
CANTD [59, 72]. These six residues are critical for immature VLP assembly.  As shown 
by disulfide cross-linking analysis, this switch segment of p10 acts as a bridge between 
neighboring CANTD domains, essentially locking the CANTD domains into an immature 
hexamer, which differs from the mature CA hexamer in its inter-subunit contacts and 
closer spacing in the lattice [72].  To date, RSV is the only retrovirus in which a 
necessary and well-defined amino acid sequence upstream of CA has been identified 
for immature assembly. Since in HIV-1 CA is directly adjacent to MA, HIV-1 is not 
believed to require an upstream switch other than the cleavage of CA from MA, allowing 
the formation of the N-terminal beta-hairpin. Both MPMV and MLV have a 12 kD 
cleavage product upstream of CA called p12. MPMV p12 does not appear to be crucial 
for immature assembly; similar to HIV-1, disruption of the N-terminal beta-hairpin 
suffices for the formation of spherical particles [134]. On the other hand, MLV p12 
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deletion mutants result in tubular, rather than spherical assembly, suggesting that MLV 
p12 may interact with CA in a manner similar to that in RSV [95, 96].  
The downstream molecular switch in RSV is the SPA domain. The cleaved 
spacer peptide between CA and NC is common to both RSV and HIV-1, but is not found 
in MPMV or MLV. Both RSV and HIV-1 spacer peptides are predicted to be part of a 
12th helix in CA downstream of the last helix of CACTD and are exquisitely sensitive to 
mutation [102, 123, 124, 126, 150, 164, 166-168]. Cryo-ET studies of in vitro assembled 
HIV-1 and RSV VLPs showed a stalk-like density underneath the organized CA-CTD 
lattice, which can be fitted with the structure of a parallel 6HB [9, 107]. Although MLV 
Gag does not have a cleaved peptide between CA and NC, the C-terminus of MLV CA 
is predicted to form a highly charged helix and mutational studies have shown that this 
charged helix is required for proper immature assembly and infectivity [127]. MPMV is 
also predicted to have a 12th helix spanning CA-NC, which overlaps with a previously 
characterized immature assembly domain similar to RSV SPA located at the N-terminus 
of the MPMV NC domain [147]. Though the recent high-resolution cryo-ET structure of 
MPMV VLPs did not show a prominent stalk-like density under the CACTD layer, the 
authors point out a ring of densities adjacent to helix 11 in CACTD [117], which might 
reflect an alternative higher-order structure involving the predicted helix. In fact, when I 
aligned the amino acid sequences of representative viruses from every orthoretroviral 
genus, I found a predicted helix downstream of the structured CACTD in all retroviruses 
except epsilonretroviridae. In alpha- and lentiviruses, the predicted helix overlaps with 
the C-terminus of CA and part or all of the spacer peptide. In beta-, gamma-, and 
deltaretroviruses, the predicted helix covers the cleavage site between CA and NC.  
 121 
 
My hypothesis is that this conserved predicted helix plays a crucial role in 
immature assembly through homologous interactions with other Gag molecules that 
expose surfaces favorable for the immature hexamer. When PR cleaves the helix, either 
by a single cut at the CA-NC junction or two cuts at the CA-SP-NC junctions, the helix 
loses its structural stability and the downstream molecular switch is flipped to mature. 
To my knowledge, this is the first time that a model has been proposed for a conserved 
downstream molecular switch in retroviral assembly. 
Future directions 
 My mutational study of the SPA domain is mostly complete. I have found the 
specific amino acid residues required for in vitro immature VLP assembly and have 
provided convincing evidence that the SPA domain forms a 6HB. An important 
remaining question to address is whether this putative 6HB is a conserved feature 
among retroviruses, or if it is only a feature of RSV. Some evidence supports both 
possibilities, as comparative cryo-EM tomography studies of RSV and HIV-1show that 
both viruses have a conserved stalk below the organized CACTD layer, but MPMV does 
not [107, 117]. However, the region downstream of the MPMV CACTD is sensitive to 
deletion [147]. It is also predicted to form a helix, which may be part of an observed 
alternative higher-order structure that promotes immature assembly [117]. 
 One method by which this question can be addressed is by measuring the helical 
propensity and multimerization states of peptides corresponding to the sequence of the 
predicted 12th helix in HIV-1, MLV, and MPMV, an experiment that is similar to what I 
described for RSV SPApep in this dissertation. One could synthesize a peptide 
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spanning the predicted helical sequence along with several flanking amino acids to 
preserve any putative upstream and downstream residues that make structural 
contributions. The peptide structure could be measured using CD and the 
multimerization state, using AUC. These relatively simple and straightforward 
experiments would quickly allow one to determine whether the region downstream of 
CACTD has a conserved structural function. 
Another curious question is whether the salt bridge found in the model of the 
putative RSV 6HB, formed by R493 of one helix and E494 of a neighboring helix, is a 
conserved feature among retroviruses. Although previous work by Keller et al. has 
shown that an insertion mutation made between the first four residues of NC and the 
sequence of this predicted salt bridge does not affect in vitro assembly in a 
baculovirus/insect cell system [126], in vitro assembly would be a more stringent way to 
assess the contribution of the predicted salt bridge to immature assembly. As previously 
discussed, cellular assembly systems may contain factors that rescue a mutant that 
would otherwise not assemble in vitro, and it is always possible that the highly abundant 
protein expression in insect cells may override the need for the charged residues.  
To test the salt bridge hypothesis, one could first mutate both R493 and E494 to 
alanines and evaluate VLP formation using in vitro assembly. If the residues do not 
tolerate mutation to alanine, which one would expect if the predicted salt bridge were 
required for assembly, then the residues could be mutated to amino acids of opposite 
but complementary charges, for example R493E and E494R, and the resulting protein 
assessed for assembly. If VLPs form following the charge reversal, this data would 
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provide convincing evidence for an inter-helix salt bridge in the putative SPApep 6HB. 
Finally, I could also make the mutations R493C and E494C, assemble a 1:1 mixture of the 
two proteins and measure any resulting VLPs for hexamer cross-linking. 
Finally, one could continue to optimize the existing SPApep crystals. Having 
already overcome the first two of three major hurdles in X-ray crystallography, 1) 
generating a protein that is soluble at high concentrations, 2) obtaining initial crystal hits, 
and 3) obtaining diffraction quality crystals, I predict that a structure of SPApep will soon 
be forthcoming. I am in the process of performing an additive screen on top of the initial 
screen condition that produced plate-shaped crystals, which will allow me to identify 
conditions favorable to the formation of larger, more regularly packed crystals that may 
ultimately lead to the structure of the putative SPA 6HB. As I have a rather detailed 
model on hand, I anticipate that the structure should be easy to solve. If there are any 
concerns about the phasing of the helices, it is always possible to use a peptide 
containing seleno-methionine in the place of one of the two existing methionines.  
An atomic-level structure of the RSV SPA 6HB would greatly contribute to our 
current understanding of immature retroviral assembly, as it could be fitted into the 
existing lower-resolution cryo-EM densities of immature cores and novel interaction 
interfaces may be uncovered. This type of information may open the door to the 
intelligent design of maturation inhibitors. My work, as presented in this dissertation, is a 
significant step forward toward a high-resolution structure of the immature retroviral 
core. 
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APPENDIX I 
UNDECAGOLD LABELING OF AN SP CYSTEINE MUTANT 
I initiated this project in collaboration with the Briggs Lab at the European 
Molecular Biology Lab (EMBL) in Heidelberg, Germany. The goal was to label an 
assembly-capable RSV ΔMBDΔPR(-11C) cysteine mutant in SP using a reagent known 
as maleimide-undecagold (Au11), assemble VLPs in vitro, take images of the VLPs 
using cryo-EM tomography, and look for additional electron densities in the 
reconstructed images. Our hypothesis was that if the RSV SPA domain did correspond 
to the stalk-like density below the organized CACTD layer, we would be able to see the 
additional Au11 density on the stalk. I decided to use the S480C mutant for labeling, 
because I found this protein to assemble at near wild-type levels when assembling point 
mutants in vitro. 
As described in previous publications using Au11, Au11-labeled protein migrate 
slower than unlabeled protein by approximately 5 kD on SDS-PAGE. Approximately 50 - 
75% of S480C is Au11-labeled when measured by SDS-PAGE (Figure I.1). I used dialysis 
into high-salt buffer (20 mM Tris, pH 7.5, 500 mM NaCl) to dialyze out unused Au11 and 
assembled the mixture of unlabeled and labeled S480C. The resulting assembly mixture 
was evaluated by TEM and VLPs were observed to form as efficiently as assembly usin 
unlabeled S480C (Figure I.2). The assembly mixture was centrifuged through a sucrose 
gradient in order to purify VLPs, which formed a strikingly gold-colored band in the 
gradient, thereby confirming that the labeled protein was incorporated into VLPs (Figure 
I.3). When the Au11-labeled VLPs were assessed by cryo-EM, however, there was an 
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abundance of electron-dense material in the background that interfered with image 
reconstruction. I believe that the background material may either be gold clusters that 
have dissociated from the Au11 complex, or it could be the product of spontaneous VLP 
disassembly. More experiments are needed to determine the source of the electron-
dense material and to find optimal buffer conditions that would prevent gold dissociation 
or VLP disassembly. 
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Figure I.1: Undecagold-labeled S480C can be differentiated from unlabeled protein 
using SDS-PAGE. The doublet boxed in red is both the labeled and unlabeled S480C 
protein.  
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Figure I.2: Au11-S480C assembles as efficiently as unlabeled S480C. The scale bar is 
500 nm. 
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Figure I.3: VLPs assembled using Au11-S480C form a gold-colored band after 
centrifugation through a sucrose gradient. On the left, the labeled protein does not 
assemble and most of the gold-colored material is found at the top of the sucrose 
gradient. On the right, assembled Au11-S480C forms a gold band at approximately the 
same density as unlabeled VLPs. 
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